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Abstract
Managing medical device monitoring processes is challenging and lacks a realtime, life
cycle tracking strategy to reduce adverse medical events and revision costs for hospital
administrators, physicians, and patients. Understanding the malfunctions of medical
devices for cardiac and orthopedic patients could save lives and reduce hospital liability.
Grounded in the business process reengineering conceptual framework, the purpose of
this single qualitative case study was to explore strategies hospital managers used to
redesign the implant recall surveillance process at one hospital in Pennsylvania. The 5
participants selected successfully implemented a medical device surveillance process that
reduced adverse medical events and revision costs. Data were collected using
semistructured interviews and a review of relevant medical device surveillance workflow
documents. The 4 themes that emerged from a thematic analysis were effective data
communication process, central data repository integration, continuous process
improvement, and end-to-end surveillance process. A key recommendation for hospital
administrators, physicians, and managers is to use blockchain distributed ledger
technology to assess device identification challenges as part of the surveillance process to
reduce health risks. The implication for positive social change includes the potential to
improve the quality of life for medical device recipients who may spend less on
healthcare services.
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Section 1: Foundation of the Study
As advances in medical device technology improve the treatment of disease,
health care managers must implement innovative strategies to redesign the device
surveillance process continuously. Implantable medical devices have the potential to
lengthen life span and improve the quality of life (Guerra-Bretana & Florez-Rendon,
2018). Although medical device implants have significant benefits, there are potential
risks that make implant products unsafe or do not contribute to improving health
outcomes (Chen et al., 2018; Guerra-Bretana & Florez-Rendon, 2018). Protecting
medical device recipients from harm requires supportive regulatory conditions and a
surveillance process that sustains an acceptable level of safety and cost for patients.
According to Wagner and Schanze (2018), understanding the existing medical device
regulatory framework is necessary to improve device monitoring and safety. Optimizing
the medical device surveillance process can have a positive impact on implant safety
(Wagner & Schanze, 2018). The need for a real-time medical device surveillance process
can potentially solve the challenges of medical device lifecycle surveillance to improve
care and reduce costs. The focus of this study was to explore potential strategies health
care managers use to redesign the medical device surveillance process to reduce adverse
medical events and revision costs.
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Background of the Problem
The problem is that managing current medical device monitoring processes is
challenging and lacks a real-time life cycle tracking strategy to reduce adverse medical
events and revision costs. Medical device implants are instruments that contribute to
improving health outcomes, yet device failures raise concerns regarding postmarket
surveillance for performance and revision notification after implantation. In 2013, leaders
of the Food and Drug Administration (FDA) issued a unique device identification (UDI)
rule to track medical device lifecycles, permitting device data transparency throughout
the supply chain process (Dhruva, Ross, Schulz, & Krumholz, 2018). In 2018, based on
UDI results from the Department of Health and Human Services data, UDI systems have
not been effective in transmitting device recall notifications, resulting in fewer incident
reportings, increased delays, and higher revision costs (Dhruva et al., 2018). The need for
better UDI monitoring transparency continues to expand as more medical devices enter
the market.
The use of medical devices has potential recall risks. Recalls of medical devices
affect thousands of patients with severe injury or death and create a financial burden on
the health care system (Lee, Berstock, Whitehouse, & Blom, 2017). The estimation of all
medical device incident reporting is 0.5% and cost Medicare 1.5 billion dollars in excess
medical fees in 2018 (Craig, O’Meley, & Carter, 2019; Dhruva et al., 2018). Hospital
managers must adopt management solutions to enable a redesign of the medical device
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recall process and minimize UDI data fragmentation to enhance recall notifications (Lee
et al., 2017). A medical device recall is an action taken to address device problems that
violate FDA law (FDA, n.d.c). A medical device recall is a removal, revision, or
correction of a product that the FDA considers violating the law and can initiate legal
proceedings. Recall notification delays can increase the risk of poor medical outcomes
due to revision time sensitivity. Managers who support medical device processes must
collaborate to improve policy compliance and standardize processes to avoid adverse
medical event complications and revision costs.
Problem Statement
Implant devices in the medical industry malfunction at alarming rates. Twelve
percent of implant devices in the medical industry fail within the first year, and
approximately 40% fail after 3-years (Cadossi et al., 2017; Gagliardi et al., 2018). The
general business problem was that postmarket implant surveillance is in decline because
of inadequate tracking systems, which result in lower recall notifications and potentially
increases health risks and revision costs. The specific business problem was that some
hospital managers in health care organizations in the United States lack strategies to
redesign the implant recall surveillance process that reduced adverse medical events and
revision costs.
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Purpose Statement
The purpose of this qualitative single case study was to explore strategies that
managers in hospital health care organizations use to redesign the implant recall
surveillance processes that reduced adverse medical events and revision costs. The
targeted population comprised of five managers in one hospital facility in the northeast
region of the United States who successfully redesigned the implant surveillance recall
process. Although medical device usage is worldwide, I focused on the successful
strategies that health care managers in the United States use for medical device
surveillance to reduce adverse medical events and unnecessary costs. Hospital managers
commonly use multiple unambiguous labeling strategies for successfully conducting
postmarket medical device surveillance to confirm compliance and to control recall costs.
Exploring the medical device lifecycle process may provide insights that avoid future
medical complications and revision costs. The implication for positive social change
includes healthier local communities for all individuals. People in society can prosper
economically when health care providers produce better outcomes, leading to further
business expansion that enhances employment opportunities for individuals in local
communities.
Nature of the Study
Researchers can choose among three standard research design methods:
qualitative, quantitative, and mixed. Qualitative research is valuable for researchers to
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guide the development of new products, services, and to gain an understanding of not
only human behavior, but on the strategies and processes that may lead to positive
outcomes (House, 2018). Qualitative research pertains to gathering data through real-time
engagement with knowledgeable participants (Clark & Thompson, 2016). For qualitative
analysis, researchers use an inductive discovery approach by which new insights develop
through face-to-face interviews using open-ended questions to explore and analyze the
strategies, experiences, and perceptions of the individuals experiencing the phenomena
(Park & Park, 2016). A quantitative research method was not appropriate for my study
because exploring the research problem does not require the testing of hypotheses to
understand the relationships between variables through a random choice of participants
and collecting to measure statistical significance (House, 2018). Some researchers
combine quantitative and qualitative methods to conduct a mixed-method study to
expand the understanding phenomena. A mixed-method approach was not appropriate for
my study because the exploration of the research problem did not require testing the
significance of variables’ relationships. My doctoral study involved understanding
manager strategies for postmarket medical device monitoring to avoid medical
complications and high revision costs. I used a qualitative method for this study to
explore strategies to redesign the process of medical-device implant recall notifications.
The potential qualitative designs I considered for this study included a single case
study, ethnography, and phenomenology. Using a single case study design entails using
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interviews, observations of normal process operations, and enables the researcher to
collect data from various participants and sources (Yazan, 2015). Ethnographic research
is about exploring and observing the cultural characteristics and behavior of individuals
for a specific circumstance and necessitates a relatively long-term data collection process
to study participants (Hammersley, 2018). Researchers use a phenomenological design
for interviewing, observing, and deriving meaning from a participant’s personal
experiences with the research phenomenon (Alase, 2017). In this study, the focus was not
on culture, behaviors, or individual meanings of experiences, but on understanding
successful postmarket medical device surveillance strategies and processes. I used a
single case study to explore a unique, critical, and complex business problem within one
organization through an in-depth description of an existing process. Researchers can use
a single case study as a suitable method to collect quality information about management
strategies from participating managers (Yazan, 2015). A multiple case study design
typically requires more time to complete than a single case study and can include the use
of several organizations and systems that are unnecessary in a single case study (Yin,
2018). I selected a single case study design to explore strategies within specific
circumstances and conditions to analyze the phenomenon using multiple sources of data.
Research Question
What strategies do hospital managers use to redesign implant recall surveillance
processes that reduced adverse medical events and revision costs?
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Interview Questions
1. How would you describe the existing surveillance process for medical device
recalls?
2. What are your hospital’s strategies to redesign the medical device surveillance
process to reduce adverse medical events and revision costs?
3. What strategies were the most and least effective?
4. What situations influenced a change in strategy leading to redesigning the
medical device surveillance process?
5. What were the barriers you encountered while implementing the strategies to
redesign the medical device surveillance process?
6. What strategies did you use to overcome the critical process redesign
challenges to mitigate medical device recall surveillance errors?
7. How does your organization redesign medical device surveillance processes for
tracking consistency in a failsafe manner?
8. How did you measure the effectiveness of the redesigned medical device
surveillance process to reduce adverse medical events?
9. What else can you share with me about your organization’s strategies to
redesign medical device recall surveillance processes to reduce adverse
medical events and possible revision costs?
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Conceptual Framework
Business process reengineering (BPR) was the conceptual framework for this
study. Michael Hammer introduced the BPR concept in 1990, and the concept is relevant
to the research study for exploring the strategies and processes for mitigating medical
device recall and postmarket tracking errors. The BPR is about redesigning processes that
change and enhance current service for better performance (Lawrence, Forbat, &
Zufferey, 2019; Mohapatra & Choudhury, 2016). By using BPR as the conceptual
framework, I had an opportunity to identify strategies that hospital managers use to
redesign implant recall notifications to reduce adverse medical events and revision costs.
The purpose of using BPR was to identify, develop, and implement process strategies to
redesign medical-implant device recall procedures to enhance current service speed,
reduce adverse medical events, revision costs, and to improve safety.
Researchers use BPR to understand existing processes and explore how to
improve outcomes and reduce costs by enhancing service, product quality, and increasing
the speed of performance (Hammer, 1990). The BPR approach helps facilitate using a
continuous and sequential cycle that involves: (a) developing business vision and
objectives, (b) identifying, scrutinizing, measuring, and prioritizing processes for
reengineering, and (c) building a prototype of the new process to improve process
performance (Hammer, 1990). Researchers can use BPR to understand existing processes
to explore how redesigning an organizational process can improve outcomes and reduce
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costs while enhancing service, product quality, and increasing the speed of performance
(Hammer, 1990).
The critical factor for my selection of BPR was its history for enabling workflow
value creation in the health care discipline to produce better outcomes. I used the BPR
model to understand how hospital managers achieve success by understanding successful
existing medical device surveillance strategies. The BPR model assisted me in identifying
and understanding how the managers successfully addressed my specific business
problem.
Operational Definitions
Adverse medical event: An adverse medical event is a random, undesirable patient
outcome consequence that may require intervention to prevent harmful results (U.S. Food
and Drug Administration [FDA], 2016).
Agnostic Tracking: Agnostic tracking is a ubiquitous static and dynamic data
detection accessibility technique that is scalable by leveraging broadband
telecommunication services and cloud technology to increase monitoring transparency
(Brissaud, Franccis, Chrisment, Cholez, & Bettan, 2019; Grubesic, Helderop, &
Alizadeh, 2018;).
Medical Device: A medical device is an instrument intended for use in the
diagnosis of a disease independent of body metabolism and affects the structure or
function of the human body without chemical reaction (FDA, n.d.b).
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Medical Device Recall: A FDA notification of a medical device problem is either
a correction or automatic revision, removal of device use, or device replacement (FDA,
n.d.a; FDA, n.d.c).
Postmarket Surveillance: Postmarket surveillance is the practice of monitoring
the medical device performance lifecycle for safety issues after the device is FDA
approved, marketed, and implanted (Wagner & Schanze, 2018).
Unique Device Identification (UDI): A UDI is a unique numeric or alphanumeric
code that consists of two parts: a device identifier and a production serial number
identifier (FDA, 2019).
Assumptions, Limitations, and Delimitations
Assumptions
Assumptions potentially include expectations that the researcher presumes to be
true without accurate verification. According to Helmich, Boerebach, Arah, and Lingard
(2015), the definition of assumptions is accounting for risk aspects that may not be
controllable by the researcher and can affect study outcomes. The researcher must verify
assumptions to separate untruths from facts to reduce belief bias and increase study
validity and rigor (Marshall & Rossman, 2016; Smith & McGannon, 2018). I assumed
that hospital managers would participate in a 45-minute interview and that all participants
possess knowledge about strategies for redesigning the medical device surveillance
process to reduce adverse events and costs. Other assumptions I made included gaining
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access to relevant organization documents that are current, complete, and can support
interview findings. I also anticipated that all participants would answer honestly.
Understanding the assumption risk factors are essential to communicate the inferences of
the emerging study knowledge.
Limitations
Limitations exist in all research studies and cover a wide range of variables.
Limitations are constraints beyond the control of the researcher that can potentially
impact the study’s outcome (Marshall & Rossman, 2016). Limitations signify the
potential weaknesses of the research that diminish the control of the researcher, require
interpretation, and can impact accurate evaluation (Podsakoff & Podsakoff, 2018).
Completing an assessment of all instruments used to collect study data is a strategy for
researchers to analyze study strengths and to mitigate limitations (Podsakoff &
Podsakoff, 2018). The most common limitations to overcome include a lack of literature,
conceptual framework application, and rigid participant perceptions (Gregory, 2019). A
potential limitation to this study is the geographic location, which could constrain
application of the findings to hospital systems within the study area rather than
throughout the United States.
Delimitations
Delimitations refer to the scope and boundaries of a study. In contrast to
limitations, delimitations are intentional study biases controlled by a researcher. The
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delimitations add study restrictions and narrow the research scope, allowing researchers
to choose which characteristics define the boundaries of their study (He, Yang, & Song,
2016). The common delimitations for this study included open-ended interview
questions, a specific number of interview questions, participant selection, and time
restraints in answering the interview questions. The participant selection criteria for this
study included hospital managers with a minimum of 2 years of experience monitoring
medical devices. In addition, I did not collect data from clinical hospital personnel
regarding strategies for reducing adverse medical events and revision costs. I also chose
the geographic location of a specific hospital to explore the postmarket medical device
surveillance process. Other non-surveillance health care management issues that may
affect implant recall, adverse medical events, and revision costs were not part of the
study. The focus of my research was to explore medical device surveillance strategies to
reduce implant adverse medical events and revision costs.
Significance of the Study
Contribution to Business Practice
Reducing postmarket medical device surveillance errors is a pragmatic approach
to proactive care and reducing adverse medical events and health care costs. Health care
managers are making incremental process changes to track the medical device lifecycle
from product design to postmarket monitoring to ensure acceptable device performance
(Chen et al., 2018). A strategic process reconfiguration approach can reduce health care
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costs by tracking revision updates in real-time from regulatory changes to assessing
claims on poorly or non-functioning devices (Chen et al., 2018). The results of the study
have the potential to inform health care managers of strategies and processes for
augmenting existing postmarket medical device surveillance practices to reduce adverse
medical events, risk, and the costs of patient care.
Implications for Social Change
An appropriate level of health care affects everyone. Regardless of social class,
income, age, education, ethnicity, or geography, all individuals should receive effective
health care (Manulik, Karniej, & Rosinczuk, 2018). Fewer disruptions in the postmarket
medical device surveillance process directly benefit individuals in the community by
improving health outcomes for all individuals and increasing social cohesion across
diverse groups (Trujillo & Plough, 2016). In addition, the effectiveness of postmarket
medical device surveillance results in higher quality products, improved services, and
higher standards of living for community members. Healthier individuals lead to healthier
communities; therefore, contributing more to local economies through tax revenues and
spending less on health care, can enable improved lifestyles.
A Review of the Professional and Academic Literature
The purpose of this single case study was to explore strategies that hospital
managers use to redesign implant surveillance processes that reduced adverse medical
events and revision costs. In this in-depth review of the professional and academic
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literature, I established the most significant facets of the research that served as the
foundation of the study. According to Onwuegbuzie and Weinbaum (2017), the literature
review is the standard way to gain knowledge and establish a study’s direction. The
literature review is an opportunity to identify different study gaps, patterns, and themes
that expand research and engage a researcher deeper into scholarly learning (Inouye &
McAlpine, 2019). Gaining an understanding of previous medical device surveillance
processes enhances understanding of the topic with the goal of producing new
knowledge.
The literature review discussion topics include an overview of BPR application to
the current medical device surveillance strategy managers use in the health care field. I
focally explored the strategies that supply chain logistic managers use to redesign
medical device recall processes to reduce adverse medical events. In the following
sections, I addressed BPR, complementary and other conceptual frameworks, the medical
device surveillance process, BPR process challenges, and innovative technology
strategies to gain a better understanding of the strategy managers use to mitigate risks in
the medical device recall notification process. The approach that I used to conduct
research encompassed an extensive search of the literature from several sources and
disciplines. The study problem is prevalent and the literature is replete with publications
regarding implant device monitoring. Device usage and adverse medical events are
increasing as the population ages globally and is creating attention for better monitoring
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solutions (Claridge et al., 2018). As the population and implants age, physician treatment
of disease takes an innovative medical device strategy approach to improve quality of
life.
The literature review consists of relevant documentation on strategies in the
postmarket medical device surveillance life cycle phase, including peer-reviewed articles,
seminal books, government, and journal sources that provide other researchers with
descriptive problem information and findings. Keywords and phrases such as health care
business process reengineering, medical devices, implants, supply chain unique device
identifiers, postmarket surveillance, monitoring medical devices, and medical device
insurance claim were used to search for peer-reviewed journal articles to conduct the
literature review. Using the Walden University library, I explored database resources
including ProQuest, EBSCOhost, ScienceDirect, MIS Quarterly, Sage Direct, Journal of
the American Medical Association (JAMA), New England Journal of Medicine (NEJM),
government publications, Google Scholar, and a collection of peer-reviewed journal
articles.
The search result scope included references published in English, and that focused
on two main topics associated with the theme of this work: medical devices and process
monitoring. A combination of research keywords included, “medical device” OR
“recall,” OR “surveillance” and “monitoring” OR” “patient safety reporting,” OR
“incident reporting system,” OR “regulation” OR “oversight” OR “vigilance,” AND
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“business process reengineering.” Moreover, I conducted an additional search by
combining previous results with keywords such as “adverse medical events’’ and
“technology-induced error” and “medical device surveillance innovation.” The sources I
used in this study were (a) 194 peer-reviewed scholarly articles, (b) seven seminal books,
(c) six government sources, and (d) one dissertation. Of the 205 sources used, 94% were
peer-reviewed, and 194 had publication dates from 2016-2019. I did not have any
difficulty retrieving a substantial number of useful resources, many of which are not part
of this study.
Synthesizing various study topic literature sources is a way to compare previous
findings to understand inconsistencies and regularities with other research approaches,
designs, methodologies, and variables (Onwuegbuzie & Weinbaum, 2017). An extensive
literature review provides the researcher with a basis to identify and support the
conceptual framework, being mindful of evidence of preconceived bias (Buhn et al.,
2017). Analyzing and interpreting recent topic literature for similarities and
distinctiveness is critical for developing new knowledge. Researchers use business
process reengineering as guides for deeply exploring redesign process strategies.
Conceptual Framework
Business Process Reengineering
The purpose of using BPR was to explore, identify, develop, and potentially
suggest redesign process strategies that improve medical-implant device recall
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procedures. BPR is commonly used in health systems to understand and redesign ongoing
process models to enhance service quality by improving process speed, safety, and
reducing costs (Grocott, Plumb, Edwards, Fecher-Jones, & Levett, 2017; Yeuk, 2017).
The resolution of medical device lifecycle surveillance can be beneficial to health care
managers who lack strategies to combine regulatory and practical health care demands to
reduce revision costs.
Applying business process reengineering. The purpose of this qualitative single
case study was to explore strategies that managers in hospital health care organizations
use to redesign the implant recall surveillance process that reduced adverse medical
events and revision costs. Business process reengineering applies to this study, given the
need for connection with innovative technology applications that can promote new core
business processes to improve product safety, quality, and reduce costs. The BPR process
is about analyzing existing process workflows that are underperforming and redesigning
processes to increase efficiencies. The BPR conceptual framework is an approach that
managers can use in the health care sector to identify the nature of the medical device
surveillance problem and to redesign process solutions. Business process reengineering
allows managers to take the first step to explore the medical device surveillance problem
from an organization and business environment perspective. Integrating processes is an
achievable use of BPR via a conceptual, shared information ledger that facilitates
tracking medical device information (Chang, Chen, & Lu, 2019). According to Chang et
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al. (2019), redesigning the ledgering process not only enables the sharing of tracking
information but also promotes a network for multilateral collaboration among supply
chain members and meets customer demands for product transparency. Sharing
information can improve synergistic collaboration among managers.
Several health care processes depend on software applications to improve
efficiencies. Business IT processes and software are vital elements for daily operations.
Health care organizations have adopted IT as a core organizational process, and software
has become an integral component in business operations (Musa & Othman, 2016).
Health care managers can apply BPR to understand how business processes and software
applications can lead to identifying strategic opportunities that potentially reduce process
weaknesses, inconsistencies, contradictions, and provide process improvement
opportunities. Business process reengineering software success factors include
technology functionality, organizational acceptance, and social employee involvement
impact (Omidi & Khoshtinat, 2016). In contrast, inadequate software application and
process design can contribute to adverse medical events and inappropriate care. The lack
of integration between software applications and human workflow procedures can
impede the improvement of efficiency and safety of any process (Sebok, & Walters,
2016). Software applications, workflows, and surveillance processes are critical for
device monitoring systems to adequately alert managers to administer prompt device
remediation or recall when the need arises.
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Identifying existing processes is essential before redesigning business procedures.
Hammer (1990) applied BPR to identify existing business processes and strategies to
redesign and transform business procedures. According to Khoshlafz, Mohsen, and
Hekmati (2016), managers can use BPR to change longstanding processes for new
processes that significantly improve business performance. Managers use BPR to
improve outcomes and reduce cost by enhancing product quality through better service
performance (Hammer, 1990). Specifically, the aim of BPR regarding medical device
recalls is to understand critical procedural aspects in the management process to improve
care quality and safety. Managers can use BPR to build on event-driven, end-to-end
process chains that can explore device status and lead to problem-solving processes
redesign for better outcomes. The benefits of using BPR is understanding the
combination of complex medical procedures that culminate in a single event instance to
incrementally implement a process redesign for lasting success (Hammer, 1990). The
benefit of using BPR methods can improve process effectiveness.
The business process concept is common in the research literature. The BPR
conceptual framework first gained attention when used by Hammer in 1990 and later
expanded in use with Champy in 1993 (Musa & Othman, 2016). The current literature
supports the application of BPR for the assessment of postmarket medical device
surveillance processes to track device recalls and to consider possible revision. Leaders
may use the BPR conceptual framework when planning a change initiative. The BPR
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framework allows managers to rethink and make radical process changes across business
workflows to improve process effectiveness and to reduce costs (Hammer, 1990). The
aim of individuals using BPR is process redesign and may involve managers adopting
new innovative technologies that enhance social change by decreasing patient treatment
cycle time and health care costs.
However, managers must make some assumptions before applying BPR. The
BPR conceptual framework depends on the assumption that the medical device
surveillance process is technical, non-linear, complex, and dynamic; but still adaptive to
process change to improve performance (Omidi & Khoshtinat, 2016). The BPR model
allows health care managers to develop and provision new processes that will enhance
medical device surveillance and reduce medical costs by lowering non-action and
unproductive activities that can increase adverse medical events. Managers who
implement the complete business logic of BPR to the device tracking ecosystem is an
applicable but challenging approach to obtaining maximum process benefit (Chang et al.,
2019). Managers that only apply specific components of the BPR conceptual framework
potentially limit results to a partial solution.
Managers face a variety of challenges adopting BPR. The challenges that
managers may experience when selecting BPR include adopting new technology,
developing accessible big data networks, and applying business intelligence feedback
applications (Zheng, Xie, Dai, Chen, & Wang, 2018). A study conducted by Hashem
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(2019) indicated that factors such as management commitment, IT infrastructure,
resource management, change readiness, data decentralization, and data analytics
contribute to successful BPR implementation. Fasna and Gunatilake (2019) further
supported the importance of understanding the characteristics of existing processes, the
type of process to be reengineered, the form of reengineering needed, and the approach
for implementing BPR to determine the success of changing the process.
Supporting Conceptual Frameworks
Other innovative conceptual frameworks that hospital managers can use to
understand complex problems and adopt new processes include diffusion of innovation
(DOI), the technology acceptance model (TAM), the sociotechnical model, complex
adoption system (CAS) model, and the Deming plan-do-study-act (PDSA) model. The
list of conceptual frameworks above align with BPR and are potential conceptual
frameworks that can increase the understanding of my study topic. For instance, the DOI
and TAM conceptual frameworks complement each other and concern the role
technology plays to create social change through the implementation and adoption of new
technology. Combining these two models can make understanding the study phenomena
robust because each model supports the application of innovative information system
technology for process improvement (Al-Rahmi et al., 2019; Sujatha, & Sekkizhar,
2019). Rogers (2003) described the DOI as having the following phases:(a) awareness,
(b) innovation knowledge, (c) persuasion, (d) decision making, (e) implementation, and
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(f) confirmation. According to Davis, Bagozzi, and Warshaw (1989), the DOI depends on
the TAM concepts of ease of use and usefulness. The dynamic use of these two models
can provide researchers with a method for accessing business processes.
Exploring business processes further using a sociotechnical lens can potentially
improve the understanding of operational business processes that are human-centric. The
application of the sociotechnical model is an alternative framework for understanding
business process design and procedure practice (Crick & Chew, 2017). Advances in
technology provide managers with process agility that enables the rapid transfer of
accurate process information to provide better services (Van der Merwe, Biggs, &
Preiser, 2018). Technology can influence the system design that connects the medical
device user holistically and sociotechnically. Technology functionality, from an
Information Technology (IT) perspective, can potentially improve medical device
lifecycle surveillance for tracking the plethora of devices, their performance, and the need
to issue a revision recall. The sociotechnical framework is an approach to analyze
technical process issues that potentially lead to technology improvisation as part of
operational business processes to deliver new useful capabilities.
The surveillance and communication of evidence-based care are critical in the
health care industry. Although current monitoring technology plays a significant role in
medical device surveillance and delivery, between 30 to 50% of all care lacks available
evidence and standard communication protocols (Sturmberg, 2018). The complex,
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unpredictable, and stochastic aspects of health care require knowledge translation and
communication that is unambiguous (Sturmberg, 2018). Complex adoption systems
(CAS) offer the potential for managers to explore and understand the uncontrollable nonlinear process aspects of health care and provide for the transition to more accurately
follow procedures to facilitate the adoption of change for better care (Bucknall & Hitch,
2018). Business process reengineering is compatible with CAS because both foci on
helping the researcher understand existing systems, discover patterns, and combine
different system elements by redesigning core processes to improve procedures. Aligning
and adopting care transitions with the complexity of process operations is a condition that
is critical to better health outcomes (Penney et al., 2018). Although the translation of
complex systems is essential, health care policy models must adapt to new system
alignments that sustain process improvements (Kitson et al., 2018). The BPR concept
provides managers with a framework to redesign complex systems into a functionally
operating system (Hammer, 1990). Business process reengineering relates to the CAS
approach to improve process efficiencies that extend beyond internal operations and can
share system information across organizations for sustainable medical device surveillance
that may reduce adverse medical effects. The Deming plan-do-study-act (PDSA) model is
an approach extending beyond manufacturing practices. The Deming PDSA model
relates to the BPR conceptual framework because both models concern medical practice
performance improvements (Baum, 2019). Business process reengineering is compatible
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with PDSA as both conceptual frameworks provide an approach that can increase the
effectiveness of modern health care through making continuous improvements. Like the
BPR, the application of the PDSA model allows managers to redesign processes to
remove barriers that can improve training, service quality, increase productivity, and
decrease cycle time, which results in minimizing the total cost of processes (Baum,
2019). The PDSA method supports change by guiding the rethinking process to produce
better outcomes.
In summary, the alternative conceptual models discussed align with the BPR
model from an innovative and continuous improvement perspective. Medical device
surveillance is a process of quality control that will evolve with new recall notification
technology. Conceptual models such as DOI, TAM, the sociotechnical approach, CAS,
and PDSA apply to this study because the exploration of the approaches allows managers
to understand the variation in the existing process before making a change decision
(Ahmed, Ahmad, & Othman, 2019). Although the other models are useful in this study,
the BPR conceptual model is the most salient approach because present business
technology creates excessive process variation and requires radical legacy system
redesign to maximize standard outcomes, decrease process times, and to reduce costs
(Vanwersch et al., 2016). Processes are a critical business asset and applying the correct
process management model allows managers to continually improve business processes
to increase customer value for sustainable business and social outcomes.
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The BPR model applies to organization processes that involve redesigning
business operations into practical and sustainable behaviors by employees. Managers use
the BPR model for guidance by empowering employees to engage in responsible actions
that dramatically improve quality, productivity, and cycle time (Hammer, 1990). Giving
managers a new starting point through end to end process accountability will help
achieve the organization’s values of meeting patients’ needs concerning reducing recall
revision cycle time and health care costs. Health care managers can use the BPR to
improve process performance that affects patients through providing sustainable and
accurate medical device lifecycles. Other conceptual frameworks, such as DOI, CAS, and
sociotechnical conceptual frameworks, support the adoption and use of innovative
process technologies by enhancing the BPR framework.
The general purpose of using the BPR is to identify, develop, and implement
process strategies to redesign medical implant device recall procedures to enhance
current service speed, reduce adverse medical events and revision costs, and to improve
safety. The objective of applying BPR is for managers to learn how to identify process
limitations and to redesign the core business processes to dramatically improve quality,
productivity, and cycle time (Hammer, 1990). The construct is about improving activities
that add to medical device lifecycle surveillance value and eliminating activities that do
not add value. Managers can innovate and adopt a new medical device surveillance
system that emphasizes the needs of the patient by establishing communication between
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database processing, which increases data transparency leading to better proactive
decision making (Hammer, 1990). The BPR conceptual framework encourages hospital
managers to rethink traditional processes and initiate new procedures that reduce adverse
medical events, fees and delivers beneficial patient value.
The BPR conceptual framework provides researchers with an exploration model
to take an in-depth overview of the concepts of tracking the medical device lifecycle from
creation to disposal. An assessment of adverse medical device events by Palojoki,
Borycki, Kushniruk, and Saranto (2017) indicated that the current problem is inadequate
postmarket medical device surveillance. Specialization and technological advances in the
medical field set the stage for deciphering and understanding complex processes, and the
BPR is a management tool that applies in modern health care settings (Grocott et al.,
2017). Process improvement and reengineering methods reduce complexity (Szmelter,
2017). Researchers can use the BPR framework to simplify and reduce process
complexity in the surveillance process of medical devices.
Health care managers have an opportunity to promote better health and business
sustainability by applying new approaches to improve the postmarket medical device
surveillance process. According to Grocott et al. (2017), monitoring constraint factors
before an adverse medical event occurs is an approach a manager can use to rethink the
process design. Rethinking and redesigning the postmarket medical device surveillance
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process serves managers as well as product developers, physicians, payors, policymakers,
and patients.
Current Medical Device Surveillance Processes
Medical devices fill a critical role in the lives and health of millions of individuals
globally. Every day, individual patients rely on medical device manufacturers to provide
safe and practical functionality. Medical device recalls potentially affect thousands of
patients with severe injury or death and creates a financial burden on the health care
system (Lee et al., 2017). A component of the general business problem is the degree of
inconsistent data repository connectivity and transparency to support medical device
identifier data tracking from multiple platform sources (Lee et al., 2017; Sheffer et al.,
2017; Whitacre, Wheeler, & Landgraf, 2017). Elements of the tracking system include
the need for transparency, accurate data, notification promptness, and compliance with
the recent federal unique device identification (UDI) law mandated to improve device
safety through proactive notification (Sheffer et al., 2017). Managers have the
responsibility to enhance data management techniques to produce better outcomes by
reducing medical device repair time and lessening financial health system pressures and
expenditures (Sheffer et al., 2017). Managers are in a needed position to close the
medical device surveillance gap by improving the transparency of monitoring and
transferring data.
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Postmarket surveillance of medical device implants is an FDA mandate that
requires a unique device identification (UDI) labeling system, which facilitates providers’
abilities to capture adverse medical event data for prompt revisions (Bayrak & OzdilerÇopur, 2017). The labeling of medical devices adds item intelligence and provides a clear
line of sight to increase the speed of product identification in the case a device creates an
adverse medical event (Fernandez-Carames & Fraga-Lamas, 2018). The UDI is a
standard alphanumeric label identification system having two parts that are machine and
human-readable. The first labeling component concerns the device identifier (DI), which
identifies the device manufacturer and the model, or version, of a specific device. The
second UDI component is the product or production identifier (PI). The PI identifies the
manufacturer lot, batch, serial number, expiration date, and date of manufacture. The
Global Standards One (GS1) organization is responsible for managing the assignment of
various identification numbering schemes that are unique to each product. Table 1 below
depicts the standard GS1 UDI labeling parameter format.
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Table 1.
FDA UDI Label Format
Humanreadable
Field Size
16

Database
Field Size
14

Manufacturing/ Numeric
Production
[YYMMDD]
Date

8

6

17

Expiration
Date

Numeric
[YYMMDD]

8

6

GS1

10

Batch/Lot
Number

alphanumeric

22

20

GS1

21

Serial Number

alphanumeric

22

20

GS1

NA

Maximum
alphanumeric
76
Base UDI
Note. Example of GS1 human-readable plain-text UDI:
(01)26187652541982(11)180923(17)200704(10)A313B1(21)9876
Retrieved from https://www.gs1.org

66

Issuing
Agency
GS1

Data
Delimiters Identifier
1
Device
Identifier

GS1

11

GS1

Data Type
Numeric

The numbering format is commonly known as a universal product code (UPC) or
barcode. Barcoding can provide managers with a secure method to collect real-time UDI
data quickly, reliably monitor medical device information, and monitor a variety of other
measurement items such as inventory and cost (Welch & Samios, 2017). The barcode
data collection process involves a portable barcode scanner and software that allows
managers to collect and assemble data by scanning machine codes from the product UDI
labels (Welch & Samios, 2017). A study by Welch and Samios (2017) confirmed that
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barcoding supports other aspects beyond surveillance services such as monitoring device
inventory data and the standardization of device categories to streamline recall
notification. Therefore, barcoding is a technological component that improves medical
device surveillance services by enhancing product lifecycle data collection for timely
information gathering when a need for further revision research exists.
UPC labeling also complies with the standard of identifying commerce products
on a global scale. The FDA UDI mandate either requires affixing the UDI label directly
on the device for repetitive use; otherwise, the device packaging must display the UDI
label. Figure 1 below depicts a generic example of the present standard FDA UDI
identification elements needed on a generic medical device label. It is important to note
that the UDI number is a barcode that is both human and machine-readable and contains
information about the item.
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Figure 1. Generic fictitious UDI medical device label design. Adapted from U.S. Food
and Drug Administration. (n.d.a). Medical devices - Unique device identification system
(UDI system. Silver Spring, MD. Retrieved from https://www.fda.gov/medicaldevices
Another type of barcode that is gaining popularity for medical device labeling is
the quick response (QR) code. The QR code is a type of two-dimensional image
encryption barcode that is a mix of pixel blocks that form a quick response, humanreadable code during decryption (Kumar & Nishchal, 2019). The QR code is immutable
and serves as a source of item authentication (Kumar & Nishchal, 2019). Figure 2 depicts
a generic example of a QR code for product identification.

Figure 2. Generic fictitious QR UDI medical device label design.
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The final UDI rule published on September 24, 2013, established a unique device
identifier (UDI) system to facilitate the identification of medical devices throughout the
supply chain distribution and a patient’s lifetime use. The final six-phase rule went into
effect on September 24, 2014. Table 2 illustrates the regulation compliance phases.
Table 2.
FDA UDI Compliance Phases
Device
Class III including life
support or life-sustaining
(LS) function

Compliance Publish Date
September 24, 2014

Regulation Format Date
Class III LS devices,
permanent UDI label by
September 24, 2015

Implantable Class I, Class
II, and Unclassified

September 24, 2015

NA

LS (Class I, Class II, and
Unclassified)

September 24, 2015

September 24, 2015

Medical devices licensed
under the Public Health
Service (PHS) Act.

NA

All other Class III devices,
permanent UDI label by
September 24, 2016

Class II or unclassified
other than LS or
implantable device.

September 24, 2016

September 24, 2018

Class I or unclassified
September 24, 2018
September 24, 2020
other than LS or
implantable device.
Note: Adapted from. Medical devices - Premarket approval (PMA), by U.S. Food and
Drug Administration. (2019). Retrieved from
https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/UniqueDeviceIdent
ification/UDIBasics/default.htm
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The FDA supports the use of the UDI system because of the potential to improve
patient health care quality by adding real-time item location functionality within the
supply chain and while in use with a patient (Brown, Kaushiva, & Chi, 2015; Resnic et
al., 2017). Resnic et al. (2017) analyzed data from 73,124 medical device patients and
confirmed that active surveillance rapidly identifies potential implantable device safety
issues for prompt revision. The objective of the UDI is to link the device data to other
databases from the manufacturer to the patient. Linking device data helps managers
reduce medical device errors, improve adverse medical events reporting, provide rapid
resolution of recalls, and reduce revision costs (Brown et al., 2015; Resnic et al., 2017;
Lau, 2017). However, the existing process is inefficient for tracking adverse medical
events and could be made more functional to monitor implant devices (Ibrahim &
Dimick, 2017). The most significant process inefficiencies include lack of UDI data
interoperability and transparency between the manufacturer, the point of care, electronic
health records, and claims. Ibrahim and Dimick (2017) confirmed that medical device
data is available. Nevertheless, monitoring processes lack adequate connectivity to issue
timely safety warnings since the existing system relies mainly on voluntarily reporting,
which increases adverse medical event detection, malpractice risk, and revision cost.
Background of Medical Device Regulation
In 1976, FDA officials entered the medical device arena after patient deaths and
harm claims involving 200,000 women using the Dalkon Shield intrauterine device (IUD)
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for contraception (Faris & Shuren, 2017). Adverse effects of pelvic inflammatory disease,
uterine rupture, and septic pregnancies prompted Congress to pass the Medical Device
Amendment bill to the Food, Drug, and Cosmetic Act in 1976 (Faris & Shuren, 2017).
The amendment gave FDA officials a framework to evaluate medical device risk using
three regulatory classes to match various devices to specific requirement levels of safety
and effectiveness. Manufacturers of medical devices must lawfully meet the risk
classification of a product before the item sells on the market by completing the FDA
assessment or premarket approval (PMA) process for Class III devices for safety and
effectiveness. The PMA evaluation is the most rigorous FDA device approval application
before marketing an item (FDA, 2019). The objective is to ensure that potential device
harm to users is minimal.
Some implants receive more attention from FDA officials than others, depending
on the intention of use and associated risk of the device, which determines device
classification. In the case of class I, II, and III medical devices, defining each type are
necessary. The FDA classifies medical devices according to an acceptable risk evaluation
that relates to the device and then applies regulation in the form of a specification to give
a reasonable assurance of safety and effectiveness (FDA, 2019). Medical devices classify
into one of three regulatory classes: Class I, Class II, or Class III. Class I medical devices
have the least amount of supervisory because the device presents minimal potential harm
to the user. Class I devices have a simple design, easy to manufacture, and have a history
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of safe use. Examples of Class I devices include tongue depressors, arm slings, and handheld surgical instruments. Most Class I devices are exempt from the premarket
notification and may be exempt from compliance with the proper manufacturing practices
regulation (Maisel, 2004). Classifying medical devices is necessary to provide end-users
reasonable assurance of safety.
Both Class II and III medical devices can have medium to high risks. Class II
medical devices are those devices that can have a moderate to high risk to the patient or
user. For example, FDA officials reported that approximately 43% of medical devices are
in the Class II category (FDA, n.d.b). Most medical devices are considered Class II
devices. Examples of Class II devices include dental implants, defibrillators, hearing aids,
and pregnancy test kits. Class III medical devices are devices that have a high risk to the
patient. These devices include life support systems, implants, or any medical device that
has a high risk of causing potential illness or injury. Class III represents 10% of medical
devices regulated by the FDA. Examples of Class III devices include implantable bone
joints, pacemakers, coronary stents, cardiac catheters, prosthetic heart valves, implantable
cardioverter defibrillators, and breast implants (Maisel, 2004). Implants are in the class
III medical devices. However, recent literature illustrates that implants may also fall
under class I or II, depending on risk. An implant class recall is severe if a reasonable
probability exists that use or exposure to a medical device will cause serious adverse
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health consequences or death (Wu & Eagles, 2016). Although medical devices benefit
millions of people, risks that can cause adverse medical events are probable.
In 2013, the FDA officials issued a unique device identification (UDI) final rule
to track medical device lifecycles for permitting device data transparency throughout the
supply chain process (Dhruva et al., 2018). The FDA UDI identification system only
applies to medical devices sold in the United States from manufacturing through
distribution to the patient. The intent of the UDI process is to enhance medical device
safety through device flaw notification of a specific device lot and for cost-effective
recall revisions (Sayle, 2016). However, current UDI monitoring data results from the
Department of Health and Human Services indicate that present device UDI monitoring
systems are ineffective and increases in device recall delays are increasing Medicare
costs (Dhruva et al., 2018). Using a clinical application alone is not improving medical
device traceability and visibility. An agnostic tracking approach may increase device
tracking transparency and have a positive impact on many health care circumstances
across multiple health systems. Agnostic tracking is a ubiquitous data mining technique
that is scalable by leveraging broadband telecommunication services that allow providers
to persistently monitor devices digitally (Grubesic, Helderop, & Alizadeh, 2018). The
medical device tracking process evaluation by the Department of Health and Human
Services suggests that using different technology tools in a symbiotic agnostic manner
potentially improves the device monitoring process.
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For medical devices that do not require a PMA, manufacturers must submit a
510(k) premarket notification checklist form. The 510(k) process is specifically for new
medical devices or revisions that are equivalent to previous legal instruments on the
market (FDA, 2019). The three types of 510(k) checklists include traditional, unique, and
abbreviated. Each 510(k) process is to ensure product quality, safety, and effectiveness.
The idea of the 510(k) approval notification process is to foster medical device
innovation through approval process flexibility.
One recall can affect thousands of patients and therefore, requires regulation and
oversight. A medical device recall is like a vehicle recall. For example, a single vehicle
recall can impact thousands of vehicle owners, and likewise, a single medical device
recall can affect thousands of individuals. A product recall is a postmarket process that
ensures failure prevention through manager remediation activities such as prompt
notification (Allard, 2017). The purpose of the postmarket process is to track the medical
implant device effectively to quickly notify the manufacturer, FDA, physician, and
patient that the equipment is faulty and may need revision. Increasing the speed of the
postmarket medical device surveillance notification process can reduce patient harm and
the frequency of medical lawsuits significantly (Bernon, Bastl, Wenqian-Zhang, &
Johnson, 2018). A study by Ball, Shah, and Donohue (2018) identified factors such as
competence and the ability to understand the root causes of manager behavior in
reporting a recall from Fortune 500 medical device organizations. Although the decision
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to report a device problem triggering a recall is voluntary, the decision to publish a
potential recall can substantially affect several aspects of an organization (Bernon et al.,
2018). Some of these aspects include the career of a manager, medical device
manufacture credibility, financial performance, and patient safety.
Postmarket Medical Device Surveillance Processes
Manufacturers continuously enhance medical device design to improve
usefulness. Implanted medical devices have become the most significant and useful
health care advances over the past 50 years (Drozda, Dudley, Helmering, Roach, &
Hutchison, 2016). Medical devices provide diagnosis options to treat disease, but the
benefit can also lead to adverse medical events if the device use exceeds capability and
malfunctions. According to Zippel and Bohnet-Joschko (2017), the current state of the
postmarket medical device surveillance process lacks a reliable tracking system to collect
critical device empirical data. An analysis of the data provides the researcher with the
potential to sort out equipment defects, rare problems, outcomes, or complications
through the device lifecycle. The implementation of such a system is given as a directive
by the FDA as a condition for active implantable medical devices (AIMDs) but lacks
system connectivity to share data. The process of sharing AIMD data is a way for
manufacturers, regulatory agencies, physicians, and patients to receive device function
and adverse medical events information in real-time (Zippel & Bohnet-Joschko, 2017).
Zippel and Bohnet-Joschko (2017) indicated that only 6% to 14% of manufacturers report

39
using the postmarket surveillance model for monitoring the lifecycle of medical devices.
One reason for the non-compliance is surveillance cost justification. Still, as the number
of medical devices increases each year, manager surveillance strategies have the potential
to reduce adverse medical events risks and costs.
Passive and Real-Time Postmarket Medical Device Surveillance Processes
Postmarket medical device surveillance data is health care data that is currently
passive and not accessible to all medical device surveillance participants with an internet
connection (Dagher, Mohler, Milojkovic, & Marella, 2018). According to Dagher et al.
(2018), any health care data is accessible electronically in real-time using an internet
connection but requires the right connectivity technology using the right interoperable
platform. The primary need is to first to collect valuable patient medical device data and
process the data into insightful patterns. The value proposition is about speed, scale, and
convenience, and sharing the medical device life cycle on a generalizable global scale is
desirable and involves designing and building a platform to collect device data (Sayle,
2016). Dagher et al. (2018) posited that a connectivity platform using blockchain or
distributed ledger technology (DLT) as a mechanism to address the health care data
accessibility, integrity, and security is a process solution to data collection. Data collected
in this manner is important for processing and sharing by addressing the speed, scale, and
convenience concerns. According to Dagher et al. (2018), the comparative performance
study of on and off-block or data chain process indicated that device data interoperability
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meets all health IT for the Economic and Clinical Health Act (HITECH) and the Health
Insurance Portability and Accountability Act (HIPAA).
For data-sharing, the concept is a paradigm shift from traditional organizational
data ownership and business and can produce effective outcomes. Dagher et al. (2018)
argued that redesigning the electronic communication framework gives data ownership at
the point of application. The right communication network design is the best place to start
medical device identification and data-sharing (Sayle, 2016). A scalable and accessible
network provides device connectivity, location, probing, and monitoring capability to
issue recalls. The UDI serves as a fingerprint to authenticate a single device out of the
many medical devices in use (Sayle, 2016). Without the use of a UDI, the authentication
requires a person to confirm and determine the device validity using several manual
resources (Yang & Zhang, 2018). Combining all sources of medical device data increases
the reliability of the device’s identification and reduces device surveillance costs (Sayle,
2016). Capturing UDI data is a valid and reliable procedure to track the medical device
lifecycle to maintain effective care that improves device surveillance to reduce adverse
medical events and to control revision costs.
Establishing a medical device surveillance system using UDI labeling within a
digital environment is challenging because of the needed investment in modern analytical
tools and the lack of legislation and oversight. According to Bayrak and Ozdiler-Çopur
(2017), the implementation of a UDI surveillance process for each medical device lacks
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legislation guidance and consistent labeling procedures across the medical manufacturing
industry, which consist of thousands of manufacturers globally. Bianchini, Francesconi,
Testa, Tanase, and Gemignani (2019) also confirmed that medical device surveillance
lacks UDI labeling transparency, causing problems within the medical device industry to
enhance safety and quality effectiveness. The current UDI registry process is ineffective
to track medical devices and to share data at all levels of care (Bayrak & Ozdiler-Copur,
2017). Bayrak and Ozdiler-Copur posited that the current model of tracking medical
devices using UDI labeling is deficient and requires better development across all
manufacturers, and throughout the supply chain to the end-user. Improving UDI labeling
can potentially augment the medical device tracking process.
Tracking medical devices is critical for many business applications. Health care
managers have the responsibility to improve device tracking surveillance vigilance to
increase patient safety, reduce counterfeits, and decrease costs (Bianchini et al., 2019).
Bayrak and Ozdiler-Copur (2017) proposed a surveillance method consisting of
continuous device data monitoring, managing the data, and transmitting the data.
According to Bayrak and Ozdiler-Copur, the challenge is to provide standard global
surveillance to approximately 22,000 and 6500 medical device manufacturers in Europe
and the United States, respectively. However, the United States is the lead manufacturer
and consumer of medical devices and generated 148 billion dollars or 43% in total global
medical device revenue in 2016 (Bayrak & Ozdiler-Copur, 2017). The United States
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continues to be the surveillance leader for domestic medical device tracking, but concern
remains regarding device traceability in the United States and on a global scale.
Surveillance is a critical part of maintaining the safety and integrity of medical
devices, and regulations serve as a significant component to modernize the device
tracking system. Melvin and Torre (2019) argued that the current medical device
surveillance systems only require legislative framework revisions rather than a process
redesign as the regulatory system is the linchpin that can either strengthen or weaken the
current device tracking system. According to Horvath (2017), the fear of timely access to
new device technologies caused the Congress representatives to mandate a less
burdensome medical device evaluation. The combination of Congress representatives
relaxing medical device evaluations and approval and current regulations are not
sufficient to control the quality and safety of marketed medical devices.
Implementing a medical device surveillance system is critical to close the device
safety risk gap. Drozda et al. (2016) argued that the FDA recognizes the need to improve
medical device performance tracking using UDI and electronic medical record data to
mitigate safety risk. The first step is to strengthen the implant device identification
system by using a UDI and a patient information implant card for routine medical data.
The UDI can ensure that medical device performance and revisions are traceable and that
the card matches the patient implant to the medical history registries for adverse effects
and safety analysis. Drozda et al. (2016) asserted that adding an implant device UDI into
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the patient electronic health record by using barcode scanning improves real-time device
safety surveillance and quality through longitudinal monitoring research. Transferring
UDI data into electronic health records will allow hospital managers to quickly enter
medical device identification data (Drozda et al., 2016). Having immediate access to UDI
data can improve device surveillance transparency, safety standards, and inventory
management.
Studies conducted concerning the link between medical devices and UDIs are
prominent. The Drozda et al. (2016) prototype coronary stent study confirmed that
linking UDIs with GS1, global trade identification numbers GTINs, the FDA UDI
database, and with clinical attributes could improve implant device tracking. Deploying
UDI surveillance content and extracting and interpreting meaningful knowledge must
include external data collection systems to increase device surveillance transparency to
prevent process delays, lower costs, and potentially increases revenue (Boisier, 2016).
Linking electronic medical data systems with manufacturer UDI barcodes extends the
device surveillance lifecycle for all implant medical devices, generalizes any immediate
revision needs, and assesses longitudinal performance for patients and hospitals (Ghobadi
et al., 2019). Although the UDI data contains critical informatics for identifying implant
devices in patients, redesigning the medical device surveillance process to include data
from hospital electronic information systems closes the reporting gap to improve quality
and safety.
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Due to the abundance of medical devices, they are moving into the remote
Internet of Things (IoT) technology pool that requires continuous tracking identification
and communication. The objective of medical device surveillance is for hospital
managers to improve implant inventory management to prevent procedure delays and
enhance device revisions proactively to lower costs, increase revenue, and prohibit injury
to the patient (Drozda et al., 2016). The challenge is for managers to establish a balance
between the right combination of technology tools to minimize device surveillance
vulnerabilities and to maximize connectivity monitoring functionality (Alexander,
Haseeb, & Baranchuk, 2018). The goal for health care managers and physicians should
be to provide accurate postmarket medical device data through reliable, interoperable
network platforms.
Although medical device surveillance requires a network monitoring system that
includes UDI identifiers, barcodes, insurance claims, and historical data repository
connections, reporting adverse medical event outcomes continues to be a voluntary and
subjective postmarket human intervention process. Medical devices cover a broad
spectrum of diagnosis, and surveillance input relies on manufacturers, physicians, health
care managers, and consumers to identify and report adverse medical events (Aslani et
al., 2018). The ability to provide an early warning system before a needed device revision
or recall becomes life-threatening is critical.
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Inadequate awareness and manual reporting efforts of adverse medical events
limit health care managers to intervene proactively to prevent impairment or serious
bodily injury. Automation of reporting processes potentially resolves some of these
reporting issues. According to Desveaux and Gagliardi (2018), automating medical
device surveillance data collection and notification functionality is a challenge that
requires redesigning the monitoring process to reduce information fragmentation and
discrepancies. The medical device tracking system should provide a transparent chain of
data. Keeping current with evolving medical device surveillance technology to ensure
postmarket regulatory compliance, safety, and proactive recall intervention can alleviate
excess revision cost, management stress, and patient risk.
Medical devices that sustain human life must comply with an expeditious FDA
premarket approval (PMA), but quick processing has the potential to increase recall risk.
According to Rathi, Krumholz, Masoudi, and Ross (2015), 36% of life-sustaining
medical devices are recall candidates, of which 4% are life-threatening. The high-volume
processing of medical devices impacts quality, which places more pressure on postmarket
surveillance (Rathi et al., 2015). Aligning the FDA PMA with medical device risk, device
class, and functional benefit is a strategy to improve safety and process effectiveness.
One way to redesign the postmarket surveillance process is to standardize UDIs across all
medical devices to close the knowledge gap between manufacturers, clinicians, patients,
and researchers (Brown et al., 2015; Jones, Mi, & Webster, 2019). Although UDI has
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fallen under legislation ruling, only 14% of manufacturers use a postmarket surveillance
process such as UDI labeling to track and monitor medical implant devices (Zippel &
Bohnet-Joschko, 2017). As more medical devices enter the market as optional treatment
mechanisms, enforcing FDA compliance guidelines across a broad spectrum of device
classes becomes a challenge.
Medical devices are part of care processes that provide several treatment options
that can improve the health of an individual. According to Lee and Bae (2017), levels of
medical device use, and benefit of that use, depends on (a) disease severity, (b) substitute
availability, (c) procedure improvement, (d) outcome improvement, (e) survival increase,
(f) quality of life improvement, and (g) cost. In terms of cost, the rapid growth of unique
medical devices accelerates expenditures that can limit economic value (Lee & Bae,
2017). Currently, any medical device that completes the FDA approval process is
reimbursable by health plans. However, the willingness to pay for the mechanism relates
to each benefit and corresponding cost and is not standardized (Lee & Bae, 2017).
Standardizing FDA reimbursement criteria for implantable medical devices can
potentially improve revenue for health care practices by reducing financial expenses.
An evaluation of medical device cost-effectiveness by McLaren et al. (2017)
indicated that combining internal and external procedures is necessary to inform
physicians how to standardize evidence-based medicine, which influences policymakers.
The increasing application of medical devices is evolving into an evidence-based need

47
approach that providers can use as an informing mechanism to make better medical,
resource, cost, and reimbursement decisions. Recent studies support the idea that
clinician monitoring of medical device health outcomes using lifecycle surveillance
evidence enhances the FDA approval process through performance feedback to the
manufacturer (McLaren et al. 2017; Melvin, & Torre, 2019). The result is potentially
better device quality, treatment diagnosis, and reimbursement procedures.
In reporting adverse medical device events, manufacturers and users of medical
devices have access to the FDA manufacturer and user facility device experience
(MAUDE) and alternative summary reporting (ASR) databases to report device adverse
medical events voluntarily. The purpose of MAUDE and ASR is to proactively prevent
adverse medical events for the patient (Yao, Kang, Wang, Zhou, & Gong, 2018). The
manufacturer and user facility device experience and ASR data are not available to the
public but contain mandatory and voluntary reports of medical device events since 1993
(Yao et al., 2018). However, on June 21, 2019, the FDA formally ended the ASR
program and is now making all report exemptions available from 1999 to 2019. Over 6
million previously hidden medical device incidents from 1999 to 2019 are now available
in the public domain (FDA, 2019). Although greater awareness may not increase
voluntary device malfunctions and recalls, monitoring as a service through a third party
may provide un-bias reporting and consistent lifecycle device surveillance.
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Adverse Medical Events and Medical Device Revisions
The frequency of medical device revisions may be the result of novel device use
and learning curve influences that influence use outcomes. Although new device
performance monitoring is critical to track procedural issues, Federici, Armeni, Costa,
and Tarricone (2017) posited that specific types of medical device technology require a
learning curve to evaluate the initial performance for reliability. A study conducted by
Kohani and Pecht (2016) found that exposing the medical device to various applications
and environmental conditions may cause the medical device to fail. One common reason
for medical device failure may be inherent to the device design because many device
ratings are for specific extremes rather than the norm (Ghobadi et al., 2019). Additional
revisions may involve a replacement, which potentially increases the risk to the patient
and incurs greater costs. However, according to Matharu, Eskelinen, Judge, Pandit, and
Murray (2018), implant revision surgery is improving by implementing medical device
surveillance processes in patients that lower the threshold for performance revisions.
Applying a medical device revision before an adverse medical event threshold occurs is
optimal and warrants further discussion.
Robust reporting is necessary to track medical devices beyond traditional
reporting from individuals, which include manufacturers, hospitals, and providers. Jang,
Choi, and Kim (2017) used a qualitative study to explain how UDI reporting systems
provide managers with a flexible tool to monitor adverse medical events from the
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manufacturer to the patient independently. Managers who use thorough UDI reporting
can manage devices and patient outcomes more effectively (Jang et al., 2017). If
managers have the opportunity to bridge the evidence gap between data registries across
the total medical device lifecycle using the UDI as the critical element of the surveillance
process, patient safety, and cost savings will increase (Zeitler et al., 2016). In this way,
medical device surveillance participants should include a broad range of connecting
groups that include device manufacturers, regulators, supply chains, physicians,
professional societies, academicians, providers, payers, and patients. Zeitler et al.’s
(2016) study highlighted the importance of improving medical device information
transparency by creating a reusable infrastructure for real-time lifecycle data collection
and analytics.
The need for an effective data collection process that serves patients by admitting
them as soon as a monitored device begins to show signs of malfunction can save lives
and be economically proactive. In a study by Zerhouni et al. (2018), the authors
illustrated that adding the UDI to a patient claim serves as a supplemental backstop data
collection process that enhances patient safety by admitting patients sooner before critical
conditions develop. Combining the UDI with the insurance claim and electronic health
records from different health care systems can provide a comprehensive medical device
data capture platform to better care for patients. In the event that a patient receives
treatment through a different health care system, the first electronic record entry will not
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capture the most current health information to determine what is causing the adverse
medical event (Zerhouni et al., 2018). Connecting different health care data platforms,
including the insurance claim processing component, may serve as a better platform to
collect, search, and access device data for efficient medical treatment.
A second significant gap to fill regarding medical device implant safety is deviceidentification data on insurance claims. Comprehensively tracking the frequency of
failure by specific brands and models can provide needed information on specific devices
(Andrew & Justin, 2017). For example, if a medical device fails, managers can learn
about the event or problems quickly from various hospitals or offices because the
insurance claim can link data from multiple hospitals. Integrating the UDI on an
insurance claim closes the device surveillance gap by connecting data systems upstream
(purchase order to manufacture) and downstream (inventory, patient, claims) to
substantiate the need for further action (Andrew & Justin, 2017). Insurance claim data
that includes the medical device UDI enriches medical device lifecycle surveillance
transparency and can help reveal more widespread problems or trends. Managers can use
insurance claims to coordinate care by determining device longitudinal performance
patterns and avoid placing patients’ safety at risk. Bowers and Cohen (2018) found that
physicians or surgeons implanting medical devices are not fully aware of all the evidence
behind the functioning or success of implanting many medical devices. Periodic
screening or testing to check if the medical devices are functioning according to a set of
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standards that are not currently part of the workflow process. Postmarket reporting of
medical device information and failures are potentially significant in improving health IT
safety and learning in-depth about the pros and cons of implanting a device (Bowers &
Cohen, 2018). Having a set of standards that spans multiple systems could save lives,
cost, and expand evidence-based knowledge of health information and technology use
safety.
Rugera et al. (2014) found through qualitative methods that regulatory authorities
do not have the resources to regulate and track medical devices manually. Despite
medical device regulation laws that govern product performance, lack of resources and
internet data source limits create a negligent surveillance system (Jung, Uejio, Duclos, &
Jordan, 2019). Data gathering constraints delay monitoring systems in collecting rich data
that can improve the current device tracking system (Rugera et al., 2014; Jung et al.,
2019). The potential surveillance barriers to overcome are complex processes and
regulations. The challenge is to redesign the surveillance process for the timely detection
of medical device issues to reduce adverse medical events and costs.
Innovative Medical Device Surveillance Process Strategies
Implementing a variety of innovative strategies to penetrate existing data silos,
sources of fixed data uniquely controlled by one entity can enhance medical device
surveillance to optimize device lifecycle monitoring. Different types of medical device
surveillance strategies include IT and non-IT solutions such as (a) using radio frequency

52
identification technology (RFID), (b) IoT technology, (c) integrative data architecture for
big data analytics, (d) social media technology, and (e) rethink and redesign traditional
processes (Haddud, DeSouza, Khare, & Lee, 2017). Monitoring the medical device
information lifecycle entails closing data gaps by activity looping raw device data from
manufactured items to potential recalls and patient recovery (Govindan, Jha, & Garg,
2016). Tracking the entire medical device lifecycle using technology and non-technology
methods from raw material to recovery is ideal for patient safety and cost reduction.
Innovative process advancements in IT provide health care managers with
solutions that can enhance data management and synthesize knowledge by using (RFID)
data collection technology (Haddud et al., 2017). Managers use existing RFID electronic
item tag system technology and the internet as a data distribution hub to transmit product
information electronically using wireless communication. The wireless RFID technology
is a tool that managers can use to continuously monitor medical devices from
manufacture to the patient using mobile cellular connectivity applications.
The purpose of RFID technology is the growing need to track items, validate
medical device identity data, prevent inferior products from reaching the market, and
from adhering to FDA regulatory policy (Basole & Nowak, 2016). The Haddud et al.
(2017) study confirmed that the practical benefit of any item with an RFID tag system is
a reliable real-time data collection system that is compliance auditable and provides
storage automation that is accessible, traceable, scalable, flexible, and adaptable.
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Three essential components of RFID technology to identify and capture device
data automatically include: (a) a unique electronic transponder or tag, (b) a handheld
scanning device or reader, and (c) a database to process and store device information
(Basole & Nowak, 2016). The challenge of deploying RFID is the integration platform
for a variety of item sensor tags that stochastically communicate and transmit data
securely without human intervention (Alaba, Othman, Hashem, & Alotaibi, 2017).
Although RFID provides managers with technology to collect and link various devices to
measure performance, recall analysis requires continuous collaboration with all members
of the monitoring system, from the manufacturer to the patient, to minimize technical and
social barriers (Haddud et al., 2017). Managers can use a new technology approach to
link and combine data collection sources to establish device monitoring networks.
Developing new networks to improve medical device surveillance is an
innovative approach. According to Alaba et al. (2017), IoT is an innovative technology
approach to establish a continuous integrative network that incorporates interoperable
communication software protocols between all surveillance members. The approach
serves to collect physical and other mobile device data that may influence device
performance (Alaba et al., 2017). Innovative medical device surveillance designers
should consider adopting a combination of monitoring strategies that track and exchange
information flow (Tyndall & Tyndall, 2018). In addition to information flow, monitoring
strategies could serve to improve device performance and reduce adverse medical events.
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Managers must consider redesigning innovative surveillance strategies that use IT
to enhance data-sharing because the recent development of integration platforms ease the
resource burden of linking a device to a data collection network, including electronic
health records. According to Powell and Alexander (2019), the barriers to overcome
redesigning innovative surveillance processes are vendor database products that limit
interoperability to exchange data. Software database vendors knowingly block health
information and are perceive the exchange of health information as an opportunity to gain
revenue (Adler-Milstein & Pfeifer, 2017). However, newer integration tools such as
application program interfaces and fast health care interoperability resources allow
managers to make inquiries and share database information beyond data ecosystem silos
without compromising vendor database functionality (Tyndall & Tyndall, 2018).
Nevertheless, automating data collection generates a large volume of data from several
sources that may be humanly impossible to manage.
One challenge for managers is to sort and monitor device data to evaluate
emerging performance patterns. The evaluation of performance patterns can help
interpret disease trends with easy access to the system for proactive device recall
management (Basole & Nowak, 2016). Despite the value of integrating, monitoring,
collecting, filtering, and analyzing data using technology from open sources, nontechnology process solutions such as collaboration and agreements between organizations
are critical to realizing the full benefit of device surveillance (Witkowski, 2017).
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Collaboration between all medical device business partners is essential to implement a
complete medical device surveillance technology system that can become part of
standard practice (Basole & Nowak, 2016). Surveillance data accessibility is critical, and
recent developments in IT to monitor medical devices for safety issues make patients
more aware of the risk and expect better device management (Yang & Zhang, 2018).
Device manufacturers, the FDA, hospital systems, providers, and patients must all work
together to form ecosystems to collect and share medical device monitoring data
transparently with complete accessibility.
Another BPR strategy for medical device surveillance is developing a robust
integrative infrastructure having a multiple-layer architecture to perform big data
analytics. Goncalves, Pereira Barbosa, Freire de Castro Silva, Fernandes Martins, and
Cheng (2018) explored data mining and big data analytics to reveal hidden relationships
between patient data, treatments, and disease surveillance. The function of big data
analytics is to process data using algorithms to interpret the data from multiple device
data exchanges simultaneously (Farahani et al., 2018). Goncalves et al. (2018) found that
big data analytics is useful for predicting outcomes because data volume, variety,
veracity, and velocity add value to the monitoring process for decision making. Farahani
et al. (2018) posited that the enhancement of big data analytics is possible by making
medical devices smart using the internet of medical things (IoMT) technology to enable
automatic big data collection selectively.

56
Furthermore, IoMT provides managers with a strategy to connect people and
devices for continuous monitoring of therapeutic applications and establishes a selfsustainable ecosystem to reduce adverse medical events concerning devices (WattsSchacter & Kral, 2019). The device communication ecosystem is made up of a
combination of participating organizations, hardware, software, and connective services
(Farahani et al., 2018). The participants include the manufacturer, hospitals, physicians,
and patients who connect devices and cloud computing for seamless connectivity,
accessibility, transparency, and usability to detect early warnings.
Creating a ubiquitous and smart communicative monitoring platform requires
coordinating multiple devices, manufacturers, service providers, patients, and numerous
protocols virtually through the exploitation of the UDI (Basatneh, Najafi, & Armstrong,
2018). Basatneh et al. (2018) posited that a smart device platform simplifies device
communication variation and allows the adoption of standard protocols to enable device
connection that eliminates the burden of configuration away from the consumer of care.
Smart device statistics can serve as a big data analysis filter to normalize the volume of
incoming data to improve decision making and device performance (Basatneh et al.,
2018). Despite the benefits of high-speed data collection through automation, managers
struggle to recognize the value of analytical applications to filter data for trends over time
as a method for finding decision-making patterns (Goncalves et al., 2018). Data filtering
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potentially allows managers to simplify analysis to support everyday application
decisions.
Innovative medical device surveillance technology gives managers a toolset to
democratize device monitoring rather than being confined to unique cases. A mobile
social media platform may serve as the transformative pioneering tool that increases
control and access to health information at the next level. A quantitative study conducted
by Al-Gayar and Shubber (2019) illustrated how e-learning, mobile health, and mobile
applications increase and improve health care. A second study by Liu and Young (2018)
explored the use of social media as a technology platform and illustrated how
applications such as Twitter and other big data research analytics provide real-time health
monitoring for making predictions. Both authors found that modeling social media data
with other datasets can lead to novel surveillance approaches to monitor and identify
changes in behavior to potentially determine if proactive medical device health
intervention is necessary (Al-Gayar & Shubber, 2019; Liu & Young, 2018). Social media
analysis may provide a rich source of data that can link several venues of care to study
the dynamics of the medical device lifecycle to avert adverse medical events before they
have an opportunity to occur.
The challenge to re-engineering the business process for medical device
surveillance may be to overcome the lack of application normalization and to obtain a
personnel skillset to deploy a new type of platform to ease usability complexity. The data
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surveillance platform infrastructure must match medical information needs but be
sharable and understandable for the medical public. Al-Gayar and Shubber (2019)
concluded that a social media medical system brings high medical monitoring by
combining social networking systems, e-learning, mobile health, and health software
applications for interaction empowerment. The outcomes can have a positive impact on
how medical device manufacturers design devices, monitor the device lifecycle, and issue
recalls reducing adverse medical events and costs. User acceptance testing (UAT) gives
managers a method to evaluate the usability of a process (Zavar & Keshavjee, 2017). A
UAT prototype will allow managers to measure user competency, effort, influences, and
support expectations through consistent observations and feedback. The purpose of UAT
is to establish self-efficacy measures to ensure that users accept the new technology
process to achieve solutions and to match functional competency levels to perform the
process tasks.
Transition
The purpose of this qualitative single case study was to explore strategies that
managers in hospital health care organizations use to redesign the implant recall
surveillance processes that reduced adverse medical events and revision costs. Section 1
served as a guide to present the study, analyze the literature, and to outline the following
sections of the study. In Section 1, I presented the background of the problem, problem
statement, and the purpose statement. The study literature review consisted of current
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knowledge, substantive findings, and the BPR conceptual framework. In the professional
literature review subsection, I discussed the current medical device surveillance
strategies, regulations, the application of BPR, and supporting conceptual frameworks.
The review of literature exposed management opportunities to improve and support the
medical device UDI postmarket surveillance process for FDA compliance.
Research that relates to UDI postmarket surveillance processes exists, and the
need for a more efficient and effective method is evident by the high medical device
recall rates. Inconsistent medical device surveillance processes continue to produce
adverse medical events that potentially increase revision costs. Published qualitative
studies of BPR factors that adhere to pre- and post-approval quality measures for medical
devices support the need for this study.
In Section 2, I discuss the details of the research project. The critical elements
include the role of the researcher, justification of the sample size, the criteria for
participant selection, and the research method and design. I outline details of ethical
research execution procedures to ensure the respect, rights, and privacy of study
participants. In Section 2, I describe data collection instruments and technique procedures
to ensure consistency and effective use of time. I discuss the details of the data
organization and analysis using software tools. Lastly, I discuss aspects of reliability and
validity to establish study trustworthiness and to ensure that the findings are dependable,
credible, transferable, and confirmable.
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In Section 3, I present and discuss the results and implications of the study. The
discussion includes a comparison of the findings to existing literature and application of
the findings to current business processes. Section 3 also contains implications for social
change, recommendations for further research, and reflections on my experience of
conducting the study. I end Section 3 with evidence supporting study findings.
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Section 2: The Project
Section 2 contains a discussion concerning the study design and the research
project completion to explore the specific problem of implant recall notification
processes that cause adverse medical events and revision costs and the need for hospital
managers to engage in a more efficient and effective process. Two critical components of
Section 2 are data collection and synthesis. In Section 2, I present a discussion on (a) the
role of the researcher, (b) participant criteria and recruitment strategy, (c) research
method and design, (d) ethical considerations, and (e) sample size justification. I also
include details about (a) data collection, (b) organization, and (c) analysis. Finally, I
conclude with a description of dependability, credibility, transferability, and
confirmability methods to ensure the study’s reliability and validity.
Purpose Statement
The purpose of this qualitative single case study was to explore strategies that
managers in hospital health care organizations use to redesign implant recall notification
processes that reduced adverse medical events and revision costs. The targeted population
comprised of five managers in one hospital facility in the northeast region of the United
States who successfully redesigned the implant surveillance recall process. Hospital
managers commonly use multiple unambiguous labeling strategies for successfully
conducting postmarket medical device surveillance to confirm compliance and to control
recall costs. Exploring the medical device lifecycle process provided insights that avoid
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future medical complications and revision costs. The implications for positive social
change include healthier local communities for all individuals. People in society can
prosper economically when health care providers produce better outcomes, leading to
further business expansion that enhances employment opportunities for individuals in
local communities.
Role of the Researcher
My role as a researcher was to serve as an instrument to conduct this qualitative
case study in an unbiased and ethical manner. Many qualitative researchers serve as the
primary investigator by collecting and interpreting data (Yin, 2018). Therefore, I abided
by the Institutional Review Board (IRB) guidelines to protect the study’s participants.
The researcher also determines the number of additional participants potentially needed
for reaching data saturation (Tran, Porcher, Tran, & Ravaud, 2017). My specific tasks
included interviewing a minimum of four participants from a single hospital organization,
managing the interview process, collecting and analyzing data, mitigating personal bias,
and making recommendations for future research while following the IRB guidelines
(Yin, 2018). Institutional Review Board policies apply to academic, community,
government, and investigative medical research protocols (Liberale & Kovach, 2017).
Following IRB guidelines ensure the ethical protection of participants.
The purpose of the IRB is to protect the welfare of human research subjects. Such
protection is the principal concern for any research involving human subjects (Friesen,
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Kearns, Redman, & Caplan, 2017; U.S. Department of Health and Human Services
[HHS], 1979). I used the principles of the Belmont Report as an ethical guideline to
protect participants in my study from harm, thereby ensuring the validity of the research.
The three critical elements of the Belmont report that enhance the research experience for
the researcher and participants are (a) respect, (b) beneficence, and (c) justice (Adashi,
Walters, & Menikoff, 2018; HHS, 1979). By showing respect, researchers provide
subjects autonomy, confidentiality, and the ability to withdraw or decline participation at
any time without question (Adashi et al., 2018; HHS, 1979). Applying the beneficence
rule allows researchers to maximize study benefits and minimize participant harm
(Adashi et al., 2018; HHS, 1979). The justice guideline is for the researcher to address
the fair and equal distribution of the study benefits and risks to participants to ensure
equal treatment of all parties (Adashi et al., 2018; HHS, 1979). I followed the principals
of the Belmont report throughout the research process.
To demonstrate IRB understanding, I completed the Walden University (ID 2906)
Collaborative Institutional Training Initiative (CITI) Program IRB coursework
requirements for student researchers. The training consisted of completing seven research
ethics and compliance course modules. The training focused on the protection of human
participants. My training and certification identification numbers are 8107976 and
31600874, respectively.
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I served as the primary research instrument to collect and interpret data to
complete the study. In the context of qualitative research, investigators are the main
research instrument because the primary focus of interest is to understand the
phenomenon under study from the participants’ perspective, often best completed by
gathering thick and rich interview data directly from the participants (Peredaryenko &
Krauss, 2013). The relationship between participants and the researcher was significant
when using a qualitative methodology because the research material was co-produced
(Raheim et al., 2016). Building trusting relationships with participants reduces participant
vulnerability, thereby gaining a deeper understanding of the participants’ knowledge
about the phenomena with their increased willingness to share (Raheim et al., 2016).
Similarly, the experiences, knowledge, and ideas of the researcher, and the participant
can enhance the quality of the data collected during the interview process (Kaliber,
2019). The challenge is keeping a minimal relationship distance between the researcher
and participant to establish a neutral professional rapport to mitigate personal prejudice,
bias, and to assure confidentially.
Privacy and confidentiality are critical elements of research. Organization
managers need assurances of privacy and confidentiality during and after the research
process (Omidoyin, Opeke, & Osagbemi, 2016). As a technical director in a health care
organization, I am familiar with interview techniques and aware of bias sources that may
stem from managers using postmarket medical device surveillance processes. Following
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the recommended interview process concepts by Kaliber (2019), Korstjens, and Moser
(2018), I reduced qualitative study bias by separating my knowledge and experience from
the participants by using a standard interview protocol and member checking throughout
the data gathering process.
The rationale for using an interview protocol is to control the interview process by
following a consistent interview plan that aligns with answering the research question.
An interview protocol is a valid method to measure an individual’s thoughts by limiting
oversights and inconsistencies during the interview process (Culbert, Ristic, Ovington,
Saliba, & Wilkinson, 2017; Horeni, Arentze, Benedict, Dellaert, & Timmermans, 2014).
A researcher uses an interview protocol to determine the essential information to obtain
and define what to ask objectively (Cypress l., 2017). Using an interview protocol (see
Appendix A) improves interview efficiency and reduces bias by providing the researcher
with a consistent process to follow for each participant interview (Rosenthal, 2016). The
interview protocol also serves as a method to replicate the process without bias.
Biases and preexisting assumptions can skew the interpretation of the study’s
results. Incorrect interpretation of the findings may diminish the transferability and
generalization of the study (Toews et al., 2017). The researcher may encounter
dissemination, confirmation, and interview biases. Toews et al. (2017) argued that
although dissemination bias in qualitative research is uncommon, deciphering known
causes of dissemination bias can provide insightful non-bias guidance. Confirmation bias,
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however, is more common because of the human resistance to change beliefs or opinions
(Miller & Jangula, 2019). According to Miller and Jangula (2019), confirmation bias can
influence data collection and analysis through subjective data filtering. Researchers can
mitigate bias and increase participant engagement by maintaining a flexible, professional
mindset approach to reduce participant interview stress and to enhance cooperation
(Antes et al., 2016). I mitigated bias by adjusting to the participant’s level of engagement,
according to the interview questions, in a professional manner to enhance a collaborative
rapport.
To avoid personal views and bias, I remained impartial by separating my
conscious experience and emotions from participant data interpretation. Personality
differences, personal characteristics, and an unstructured question process can potentially
create a bias (Hilgert, Kroh, & Richter, 2016; Kaliber, 2019). According to Levashina,
Hartwell, Morgeson, and Campion (2014), adding interview structure and standardizing
the interview process for all participants can minimize off subject variation and bias. I
assessed my potential biases by being aware of preexisting assumptions. I remained
objective and maintain impartiality by using a semistructured interview protocol
approved by Walden University’s IRB, and by conducting member checking to validate
the participants are sharing what they intend to share and that my interpretation is correct.
I also acknowledged that my professional experience might cause research bias and did
not interview participants with which I have any professional or personal relationship.
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Throughout the interviews, I remained professional, follow the interview protocol with
consistency, and use active listening skills to normalize the participant interview process
and to mitigate bias in my research.
Participants
Selecting study participants with relevant experience is critical to authentic
research. Defining participant eligibility criteria ensures that the participants’ expertise
and characteristics align with the research topic to eliminate the potential for fraudulent
responses (Chandler & Paolacci, 2017). The participant criterion for this qualitative
single case study included hospital managers with at least two years of postmarket
medical device surveillance process experience, at least two years of business process
redesign decision authority, and hospital managers who were successful in implementing
process redesign.
Researchers depend on accessing appropriate participants within the business to
provide pertinent and relevant data that improves the understanding of the current realworld issue and to align participant knowledge with the research question (Palmatier,
2017). In addition, recruiting participants with experience eliminates barriers such as lack
of knowledge and inability to articulate opinions in a reflective manner (Duncan &
Hagglund, 2018; Ledford, 2018; Palinkas et al., 2015). Eligible participants provide a
rich source of relevant knowledge that improves single case study validity (Duncan &
Hagglund, 2018; Ledford, 2018). Failure to recruit knowledgeable participants can
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reduce the efficacy and potential value of the study (Juurlink, Bavera, Sclafani, Petrov, &
Reid, 2018). Recruiting participants who are knowledgeable about the study issue ensures
a better understanding of the research problem and question. Gaining access to potential
participants is critical. According to Cridland, Jones, Caputi, and Magee (2015),
researchers can gain participant access through directories, Internet searches, and inperson recruitment meetings. I gained access to participants using the organization’s
directory list and followed up with an email to contact potential participants (see
Appendix D).
I gained access to participants by completing the hospital research IRB
requirements at the site and complied with the organization’s IRB criteria to obtain the
correct organization authority for access (Dichter et al., 2019). Once I met the hospital
and Walden University IRB requirements, I proceeded to contact potential participants
relevant to the study. I obtained permission from Walden University’s IRB and from the
hospital organization’s IRB (see Appendix E) before contacting potential participants by
any form of communication.
I established a relationship with the participants by sending a formal invitation via
email (see Appendix D), sharing the purpose of my study, and presenting each manager
with an opportunity to participate in the doctoral research voluntarily, and without any
consequences, if there is a decision made to withdraw from the study at any point and for
any reason. The email invitation included detailed information regarding interview time
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expectations, ethical protection, participant confidentiality, response anonymity, and data
storage security during and following the research study. Establishing a symbiotic
working relationship breaks down role conflict between researcher and participant,
engages participants to present their views, and helps co-interpret the phenomena
(Raheim et al., 2016). I established a working relationship with the participants by
engaging them through consistent and purposeful communication using an initial email
and further email and telephone discussions to confirm participant eligibility, recognize
and acknowledge their expertise, and to form a professional rapport. I developed trustful
relationships by meeting potential participants in private office rooms, assuring
confidentiality, explained the consent form (see Appendix C) in accordance with the
stringent academic code of ethics, and asked them to reply to the informed consent form
email with the words I consent before beginning the interview.
Research Method and Design
I used a qualitative single case study and purposeful sampling, methodological
triangulation, participant interviews, member checking, and the review of relevant
process documents to explore strategies to address the specific business problem. A
qualitative single case study is a flexible method researchers can use to gain
understanding and insight into individual business problems through participant
perspectives by exploring how and why a process operates in a real-life setting
(Gaikward, 2017; Rolfe, Ramsden, Banner, & Graham, 2018; Rosenthal, 2016). A
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qualitative case study is applicable for exploring issues by understanding the context of a
phenomenon through an exhaustive investigation of a bounded system (Creswell & Poth,
2018; Kegler et al., 2019). I focused on the rich context of participant real-life business
activity, experience, and knowledge to gain an insightful understanding of the
phenomena under study.
Research Method
Researchers select one of three methodology approaches to conduct research. The
three methods are qualitative, quantitative, or mixed methods (Creswell & Poth, 2018).
Qualitative and quantitative methodologies are the dominant approaches to addressing the
research question and hypothesis, the latter being a component of quantitative studies. A
researcher uses a qualitative research method to gain a deeper understanding and rich
insight from the participant’s perspective (Hamilton & Finley, 2019). Qualitative research
is valuable for researchers to guide the development of new products, processes, services,
and to gain an understanding of strategies that lead to specific outcomes (House, 2018).
According to Rolfe et al. (2018), qualitative research is more relevant in the health care
field because the co-partnering relationship established between participants and the
researcher helps address the problem by establishing which priorities to explore in a
somewhat relaxed interview setting. Bansal, Smith, and Vaara (2018) posited that the
breadth and variety of qualitative research offer more significant insights into
understanding complex problems. The scope of a qualitative methodology has the
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advantage of being broad enough to capture new meaning for a more in-depth
understanding of a complex phenomenon.
In contrast, some scholars argued that quantitative research is more objective.
According to Rendle-Short (2019), a quantitative methodology relies on numerical data
that represents a narrow consensus of perception, and instead focuses primarily on
statistically analyzing variables. Hammarberg, Kirkman, and de Lacey (2016) stated that
quantitative research represents a broader sample of a population and is objective.
However, researchers can manipulate the collected data by sample size and make
statistical assumptions that do not identify and quantify the in-depth meaning of the
phenomena through engaging directly with study participants (Taguchi, 2018). Some
scholars argued that a mixed-method approach provides a balance of data collection by
using both qualitative and quantitative methodologies to enhance the trustworthiness of
research claims (Cohen, Manion, & Morrison, 2018). According to Taguchi (2018), the
combination of methods may dilute researcher rigor by adding multiple statistical factors
that skew qualitative outcomes.
I selected a qualitative approach to explore manager strategies regarding
postmarket medical device surveillance processes to reduce adverse medical events and
revision costs. Using a case study, researchers collect unstructured data from participants
and observe processes (Gaikwad, 2017). Qualitative research pertains to the analysis of
unstructured data to answer how and why questions within a real-world context (Yin,
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2018), and is the primary reason why I selected a qualitative approach. My intention in
this study was not to quantify different numerical values and is not a preliminary method
that leads to quantitative or mixed-method research. Since structured statistical analysis is
not required, quantitative and mixed-method approaches were not appropriate for this
study. Instead, in using the qualitative approach, I was able to easily obtain the breadth of
knowledge I was seeking in working directly with hospital managers.
Research Design
There are several research designs to choose from in conducting a qualitative
study. As choosing a research design is a process that directs the manner in which
information will be gathered, it is essential to select the design most appropriate for
gathering information-rich insights that align with the research question (Benoot, Hannes,
& Bilsen, 2016; Knapp, 2017; Yin, 2018). I considered three qualitative research
methods: case study, ethnographic, and phenomenological, before selecting a case study
design with interviews to address the research question.
A case study is a research method that is commonly used as a strategy to
investigate a phenomenon. According to Yin (2018), a single case study research design
is used to generate insights from in-depth inquiry to study complex phenomena within a
real-life context. According to Saunders, Lewis, and Thornhill (2016), the case study
design can include a person, change process, activity, program, or event and is the
primary vehicle for generalizing a study’s findings (Creswell & Poth, 2018; Yin, 2018).
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Researchers use case study designs to conduct an exhaustive exploration of either a single
case or multiple cases to understand a concept from different angles and by using diverse
sources (Netland, 2016). A single case study method is appropriate for this study because
the emphasis is to understand strategies unique managers use to successfully monitor the
medical device lifecycle process to reduce adverse medical events and revision costs. The
ethnographic design is a common qualitative synthesis approach (Benoot et al., 2016) and
appropriate to explore shared values, beliefs, and behaviors of a culture or group
(Saunders et al., 2016; Creswell & Poth, 2018). Because the objective of this study was to
explore process redesign strategies, it did not require the analysis regarding shared
cultural values, and I did not choose the ethnographic design. A phenomenological design
is not appropriate for this study because the intent is not to explore the lived experiences
of individuals (Creswell & Poth, 2018). Rather, I used a single case study design to
obtain rich data from individual participants to answer the research question.
Data saturation occurs when participants repeat the same information, and no new
information in the data leads to new emergent themes. Achieving data saturation is when
a researcher determines that the data collection and analysis process produce minimal or
no response change (Tran, Porcher, Falissard, & Ravaud, 2016; Tran et al., 2017).
Researchers achieve data saturation by collecting all data relevant to the case study until
nothing new emerges (Tran, & Ravaud, 2017). I conducted semistructured interviews and
review process documents to obtain data saturation, and considered the data set complete
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when the same information from participants was redundant, and no new knowledge
from the data produced additional themes. I asked open and probing interview questions
to all study participants until the responses did not generate new information, ideas, or
themes indicating data saturation.
Population and Sampling
The population for this qualitative single case study consisted of medical device
hospital managers from one hospital in the state of Pennsylvania. The study hospital
organization population consisted of 8 hospital managers who monitor medical device
surveillance processes. Researchers use a purposeful sampling strategy to select
population participants who can identify and contribute rich, comprehensive knowledge
to address a study’s research question and can bring insight to a specific problem
(Lavallee et al., 2017; Marshall & Rossman, 2016; Setia, 2016). Purposeful sampling is a
standard, nonrandom selection method used to confirm that participants who have the
experience, knowledge, and capability are in the final sample used to address the research
question (Benoot et al., 2016; Setia, 2016; Yin, 2018). Purposeful sampling requires
critical planning, such as defining criteria to serve as a guideline to recruit potential
participants who can provide rich information about the topic (Benoot et al., 2016;
Rosenthal, 2016). I used purposeful sampling in this single case study to identify five
managers from the study hospital population who have specific knowledge of the study
topic to reduce interferences and who provided rich data.
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The participant sample included hospital managers with 2 years of postmarket
medical device surveillance process experience, possess decision support making
authority, and who have successfully implemented strategies to redesign implant recall
notification processes that reduced adverse medical events and revision costs in their
organization. I used purposeful sampling to ensure that the sample for the research
included hospital managers who have experience and decision-making authority
implementing strategies to enhance medical device lifecycle surveillance. Through
purposeful sampling, I identified five potential participants who had the appropriate level
of experience and were able to contribute to the study topic knowledgeably and provide
data that helped answer the research question.
Determining sample size is critical and recruiting more than four participants
depended on whether four participants is sufficient to achieve data saturation. Firm
guidelines to determine the sample size for qualitative research are sparse because size
determination varies and is partially dependent on the phenomena under study, the
research question, and the richness of the data provided (Boddy, 2016; Elo et al., 2014;
Hennink, Kaiser, & Marconi, 2017). However, previous studies are useful for estimating
sample size and reaching data saturation and can provide researchers with a parameter for
justifying sample size (Boddy, 2016). Yin (2018) suggested a minimum sample size
between three to five for a case study. A qualitative research study in a health care setting
conducted by Cronin (2014), concerning the implementation of new process strategies,
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revealed the researcher was able to reach data saturation by interviewing five
participants. In another qualitative study regarding strategies to mitigate process risk,
Bowman (2015) reached data saturation by interviewing four participants. Because my
study was a single case study about process strategies such as in the previous case studies
mentioned, I used five participants as the sample size from one hospital organization
located in Pennsylvania. I reached data saturation using five interview participants.
Although I identified five potential participants for data collection, I reached
greater data saturation by combining multiple data sources. Data saturation is not only
about the volume of information gathered, but rather the ability to conduct the research
until there is no new information shared (Weller et al., 2018). Researchers employ data
triangulation to add credibility to a study’s findings by collecting and verifying data using
multiple data sources to analyze the same event, concept, or variable (Kern, 2018;
Saunders et al., 2016). I performed semistructured interviews with business managers;
used organization documents, including process documents, policies, and metric reports;
and conducted a thorough review of the literature to support the collected data to ensure
data saturation.
I explored two additional qualitative sampling approaches for this exploratory
study: (a) snowball and (b) quota sampling methods. Snowball or network sampling is a
nonprobability research method for identifying additional hard to find participant or
informant sources (Heckathorn & Cameron, 2017; Saunders et al., 2016; Suri, 2011).
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According to Marcus, Weigelt, Hergert, Gurt, and Gelleri (2017), the snowball sampling
technique is a disadvantage because the method potentially adds bias due to participants
recruiting close associates to participate in the study. I did not use snowball sampling for
this study because participants are not difficult to find, and there is no need to
recommend other associates. Quota sampling is a nonprobability, nonrandom sampling
method that is appropriate for studies involving more than one sample population or
subgroups based on participant criteria, accessibility, and availability (Saunders et al.,
2016; Setia, 2016). According to Ochoa and Porcar (2018), the reason researchers
implement quota sampling is to select participants to ensure the final sample aligns with
the target population, subgroups, and any study variations that enhance data collection. I
did not use the quota sampling method because only one sample population was
necessary for data collection in the study.
Ethical Research
Researchers must consider ethical components during data collection. Ethical
research execution concerns respecting and protecting the privacy and rights of study
participants. The IRB guidelines are intended for researchers to protect participants
ethically and are mandated in the United States by the Code of Federal Regulations
(Miracle, 2016). The IRB process first began in the United States in 1974 in response to
the Belmont Report to protect study participants. The Belmont Report is a guide and
includes the three core principles of respect, benefice, and justice. The three core
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principles ensure research is conducted ethically (Brothers et al., 2019). Researchers use
the respect principle to protect the participant’s autonomy and the right to participate or
withdraw from the study without reason and at any time (Miracle, 2016). The
beneficence principle relates to the need for researchers to protect the participant from
harm by minimizing risks and maximizing study benefit (Miracle, 2016). Researchers use
the justice principle to focus on safeguarding the participant from any exploitative
procedures (Miracle, 2016). Federal regulations provide ethical guidance for research
projects that involve human subjects and require IRB approval before any research
activity commences (Liberale & Kovach, 2017). To ensure my research processes are
appropriate and will do no harm to participants, I completed the Collaborative
Institutional Training Initiative (CITI) (ID 2906) training for student researchers. My
training and certification identification numbers are 8107976 and 31600874, respectively
(See Appendix B).
Based on the Belmont Report and Walden University IRB guidelines, I obtained
IRB approval before contacting the participants and collecting data. After receiving
Walden University IRB approval, I notified the organization by email of Walden
University’s IRB approval to collect data using semistructured face-to-face interviews. I
contacted leaders at the organization via email to present the purpose of my study and to
request names of potential participants that meet the inclusion criteria of having specific
experience and knowledge with the medical device surveillance process. I emailed
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potential participants a recruitment letter (see Appendix D) and the informed consent
form (see Appendix C). In the email, I included instructions for the potential participant
to reply via email if they are willing to take part in the study. If the participant had
understanding of the study well enough to make a conscious decision to participate in the
study, I asked the participant to respond by replying to the email with the words I consent
to my original email thread and attach the informed consent. The recruitment letter
contained contact information for potential participants to contact me directly to address
any concerns or questions.
When interviewing participants in any study, obtaining written consent is
necessary. Obtaining informed consent is a mandatory element to conduct ethical
research involving human subjects (Gaikwad, 2017; Liberale, & Kovach, 2017). The
informed consent form ensures that potential participants engaged in the research have
relevant yet comprehensible information about the study to decide about participating in
the research (Karbwang et al., 2018). According to Karbwang et al. (2018), the informed
consent form is a detailed study explanation of the purpose, procedures, participants’
rights, welfare, safety, risks, benefits, withdrawing methods, disclosure about
participation without incentives, and confidentiality. I emailed the informed consent
form, included in Appendix C, to each potential study participant and gave the potential
participant the opportunity to ask questions, review their rights as outlined in the consent
form, and to obtain their consent via email without coercion pressure. Researchers use
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informed consent to provide the potential participant with a clear understanding of their
rights and impact (Saunders et al. 2016). I ensured that the potential participants had a
clear understanding of the informed consent form, and I followed up with a telephone call
for further explanation, if requested, before the participant replied I consent with an
email. I will email each participant an informed consent form and ask voluntary
participants to reply I consent to my original email thread and attach the informed
consent form to their reply email as part of the ethical research process.
Through the informed consent process, I explained to participants that they have
the right and freedom to withdraw from the study at any time without reason or
consequences by notifying me via email or telephone. The consent form allows the
participant to voluntarily withdraw from the study without cause (Angelos et al., 2018). I
made the participants aware that participation is entirely voluntary without compensation
or incentives for their participation. I stored the information on a removable external hard
drive with encryption and dual password authentication. The hard drive will be stored in
a safe with a combination lock for a minimum of five years before deleting the files
permanently. I will be the sole person to have access to all stored study files in the safe. I
included the Walden University IRB approval number 02-28-20-0614432 on the final
document manuscript.
Respecting and protecting the privacy and rights of study participants is critical.
Researchers commonly use pseudonyms to protect the identity of research participants to
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ensure data confidentiality and privacy (Surmiak, 2018). According to Leibenger,
Mollers, Petrlic, Petrlic, and Sorge (2016), the use of pseudonyms sustains participant
confidentiality and provides research privacy for new knowledge development and
ensures legal protection. Allen and Wiles (2016) concurred that assigning aliases to
research participants confirms data confidentiality, privacy, identity protection, and adds
the psychological benefit of participants feeling comfortable to offer rich study content
liberally. I used participant pseudonyms such as Par 1 through Par 5 to reference the five
research interview participants for the study. I will securely hold and protect the original
names of the study participants from any revealing documentation or circumstance that
could identify any participant or the organization at which I am conducting the study. I
will be the only one to know the true participants’ identities, and I will be solely
responsible for keeping identities confidential. All data obtained from the participants
during and after the study will be confidential. The participating organization and
participants’ privacy will always be protected.
Data Collection Instruments
There are several ways in which to collect data. In qualitative research, a
researcher becomes the primary instrument for data collection (Clark & Veale, 2018;
Marshall & Rossman, 2016; Yin, 2018). According to Marshal and Rossman (2016), a
researcher’s data collection objective is to gain access to participants to collect and record
the data for future analysis and interpretation. I served as the primary instrument for data
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collection for this qualitative single case study using face-to-face semistructured
interviews. Researchers can use semistructured interviews as a method to collect data
about a specific phenomenon from a participant’s perspective and experience with a
phenomenon without constraints (Heath, Williamson, Williams, & Harcourt, 2018). I
asked the participants nine open-ended interview questions that have no restrictions,
constraints, or the need to choose one out of several possible responses.
Although procedures exist to conduct a qualitative semistructured interview, an
interview protocol can guide the researcher to ask the same questions consistently to each
participant to avoid skewing the data in any way. A researcher may gain in-depth
information and uncover new knowledge from a participant’s subjective responses when
answering open-ended questions (Clark & Veale, 2018). According to Weller et al.
(2018), open-ended and follow up probing questions allow study participants sometimes
to offer unexpected information when answering interview questions. I followed an
interview protocol to ask questions consistently (see Appendix A).
I ensured capturing the accurate and intended responses from the participants by
using member checking. Member checking is a technique for exploring the credibility of
response results by doublechecking with participants that a researcher’s analysis of the
interview data is the correct interpretation (Birt, Scott, Cavers, Campbell & Walter,
2016). According to Baillie (2015), member checking is the technique of choice to
confirm researcher understanding and to affirm credibility. I conducted follow-up
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sessions after the initial data collection interview. During this session, I shared a brief,
written interpretation of what I believe they have shared to assess my accuracy in
understanding their intended meaning. Member checking in this manner serves to
decrease incorrect interpretation and enhance the trustworthiness of the study.
Data Collection Technique
Researchers can use a variety of primary and secondary data collection techniques
to gather information from multiple sources to gain insight relevant to the study.
Conducting interviews and reviewing relevant documents are the most common data
collection techniques for case study research. According to Rosenthal (2016) and Yin
(2018), researchers must complete many data collection activities such as (a) develop an
interview protocol, (b) conduct the interview and collect data, (c) audio record the
interview, (d) transcribe the audio recordings, (e) conduct member checking to confirm
data interpretation, and (f) review existing relevant documents. Interview protocols and
reviewing documents are strategies that a researcher can use to collect data (Rosenthal,
2016). The techniques that I used to collect data included semistructured face-to-face
interviews and document review.
The location and time of the interview can potentially influence the data
collection process. Researchers should conduct interviews in a setting that is convenient
and comfortable for the interview participant, and that can occur using several
communication mediums (Rosenthal, 2016; Saunders et al., 2016). Current and valid
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interview communication mediums include face-to-face interviews, telephone
conferences, or using an electronic application such as Skype video chat (Rosenthal,
2016). In the study being conducted, I used the communication medium of face-to-face
interviews and choose a location for the in-person interviews. I scheduled an interview
place and time that was secure, private, and convenient for the participant to speak freely
and without interruptions.
I initiated data collection after IRB approval, beginning with emailing potential
participants the informed consent form and the recruitment letter. Participants provided
consent by replying I consent to my original email thread. I then completed the data
collection process below:
1. I obtained site authorization from executive leadership to conduct the study.
2. I performed a trial run with an expert participant to field test the interview
protocol and the interview questions.
3. I identified and recruited participants. I emailed the informed consent form to
potential participants. The participant email contained instructions to respond
via email with the words I Consent if they are willing to take part in the study.
4. I scheduled and conducted face-to-face semistructured interviews and agreed
to a place, date, and time. I reserved a private location to conduct the 45minute interviews using an interview protocol.
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5. When I met the participant, I introduced myself, reviewed the informed
consent, and answered any questions. I collected study data using a ninequestion interview protocol (see Appendix A) to conduct the semistructured
face-to-face interviews using opened-ended questions.
6. I audio recorded each interview and transcribed the responses into a Microsoft
Excel workbook folder for each participant.
7. I completed a preliminary participant response summary of the transcript.
8. I scheduled and conducted member checking to share a brief, written
interpretation of what I believed they have shared with the participants within
48 hours for further data interpretation and inform the participants that they
can add any information if necessary.
9. I collected secondary data during the interview and member checking
sessions. I asked for permission from participants to share relevant documents
to support the interview responses. Relevant documents included charts,
graphs, spreadsheets illustrating strategy performance metrics, and other
internal documents that the participant determined essential and supported the
participant’s point of view. Specifically, I asked to share non-confidential
documentation regarding postmarket medical device surveillance process
workflow activities including device manufacturing, FDA recall notification
letters, internal recall notification time logs, internal notification emails,
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device removal, revision, correction completion logs, aging notification recall
logs, unique device identification data, and business process workflow
mapping that illustrate the end-to-end surveillance recall notification process.
10. I stored data on a password-protected external flash drive. I secured the
external hard drive in a home office locked safe for five years before
permanently deleting electronic data files.
Interview Protocol and Interviews
Using an appropriate interview protocol and set of interview questions to obtain
the most salient information from participants can be challenging. Field testing is a
common way to assure the interview questions, and the protocol used to guide the study
is effective (Kallio et al. 2016). According to Kallio, Pietila, Johnson, and Kangasniemi
(2016), a semistructured interview protocol is a strategic approach that allows the
researcher to focus on specific study details to increase consistency in the data gathered
and aid in affirming the reliability of the study. The field test helped me to supply the
correct information on the interview protocol while allowing for a free flow of
information that sometimes goes beyond the bounds of the protocol.
Potential disadvantages of using an interview protocol include poor quality of
data, sample size, lack of researcher experience, and participants giving verbose
responses. However, following a semistructured interview protocol can lend to data
accuracy and consistency. A study by Kallio et al. (2016) indicated that a rigorous
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interview protocol gives a researcher the advantage of asking specific questions to the
aim of the study that contributes to quality findings. Researchers use semistructured
interview protocols to focus on specific content and to probe for in-depth answers to
increase data quality and reliability (Gaikwad, 2017; Saunders et al., 2016). Another
advantage is potentially gaining opinions and perspectives directly from the participants’
experience (Rosenthal, 2016).
Researchers use semistructured interviews to explore participant thoughts,
perceptions, and experiences. Using a combination of open-ended and probing questions
can encourage participants to explain responses in greater depth are common and useful
in qualitative research (Rosenthal, 2016; Saunders et al., 2016). I used semistructured
interviews, asked open-ended questions (see Appendix A), and used probing questions to
obtain rich qualitative data. Researchers also use field-testing to ensure the
appropriateness and accuracy of the interview questions. Field-tests are appropriate for
small sample sizes using a single case study design to match the interview questions with
the research question (Kaae et al., 2016; Kallio et al. 2016; Purswell & Ray, 2014).
Conducting the field test with an expert allowed me to feel confident that the interview
questions were appropriate to gather the most comprehensive and salient responses from
the participants.
Achieving accuracy and rich data from the interviewing process include several
factors. According to Chandler and Paolacci (2017), the quality of data depends on
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participant eligibility, experience, and integrity in answering the interview questions to
ensure trustworthiness. According to Morse and Coulehan (2014), the participants’
relationship with the researcher can have a response impact. In this study, I aimed to
remain objective and established a rapport with the participant to gain the most accurate
information without overtly contributing to any opinion shared by the participants. A lack
of researcher experience can influence the interview data (Raheim et al., 2016). Levit,
Huang, Chang, and Gong (2017) posited that transcribing participant responses can be
difficult due to the potential to create interpretation error out of both researcher
inexperience and the nature of conducting semistructured interviews. Reviewing
interview audio recordings and using the member checking process are techniques the
researcher can use to clarify and interpret ambiguous responses for accuracy (Levit et al.,
2017). I used the interview protocol, audio recorded the interviews, and used member
checking to minimize inconsistencies and enhance the data collection technique process.
Documentation
The advantage for researchers reviewing relevant documents is to compare the
interview information with historical organization operation data of the organization
under study. Marshall and Rossman (2016) posited that organization documents could
serve as a data source that supports and reassures the study’s findings. According to Yin
(2018), the advantages of using document review are that the data are a source of
background information, collecting the data is unobtrusive, and the data may include
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other important themes. Collecting data from relevant documents is an approach to add
rigor to a study (Cardno, 2018). I used document data as an additional resource to support
the study findings.
Using both document and interview data can enhance the study findings to answer
the research question. Combining document reviews with interviews is a triangulation
method that contributes to study reliability and validity (Fusch, Fusch, & Ness, 2018).
Validating one set of data with the second set of data minimizes inconsistencies (Yin,
2018). Reviewing relevant documents is an approach researchers use to crosscheck to
ensure a consistent, accurate representation of the phenomena in relation to the data
shared by the participants during the interview and member checking processes (Clark &
Veale, 2018; Korstjens & Moser, 2018). Comparing operation documents to the actual
interview data is a way to ensure data integrity and address the research question most
effectively. I reviewed relevant organizational documents such as medical device
surveillance process procedures, device notification policies, and recall measuring
metrics to increase my understanding of the medical device surveillance processes and
compared the document data with the interview information to accurately understand the
existing strategy process that related to addressing the research question.
While reviewing relevant documents is often valuable, there are disadvantages.
Reviewing relevant documents is potentially time-consuming; the information may lack
detail, version control, or have an organizational policy and proprietary limits that restrict
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the researcher from selecting specific data (Cardno, 2018). Cardno (2018) posited that
because documents are not produced for research purposes, they may contain insufficient
detail as an accurate research data source. I reviewed relevant documents that were
appropriate and salient to crosscheck the interview data and provide plentiful
information.
My data collection technique activities included member checking. Member
checking is a common technique that researchers use to provide participants with an
opportunity to review a segment of the transcript material and summary to ensure that the
researcher’s interpretation of what the participant shared was interpreted correctly by the
researcher (Birt, Scott, Cavers, Campbell, & Walter, 2016; Drisko, 2016). According to
Birt et al. (2016), member checking is a critical, time-consuming and rigorous process
that actively involves confirmation of the researcher’s interpretation of the interview data
to improve the credibility, validity, and accuracy of the data. I reviewed each interview
question, summarized responses, and revised the interpretations by changing or adding
more information to clarify responses and enhance research credibility. According to
Roberts, Dowell, and Nie (2019), the integrity of data collection and analysis are
demonstrated by collecting the data with honesty, openness, and with impartiality. I
conducted member checking within 48 hours after the initial interview by providing the
participants with a brief synthesized summary of my interpretation of their responses to
the interview question. I scheduled a time to return to participants with the summary to
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complete the member checking process and to review my interview data interpretation for
accuracy. In the event information needed to be corrected or added, the participant was
able to do so during this time, and I included their changes or updates in the data analysis.
Data Organization Technique
Qualitative researchers can use a combination of tools to compile and organize
single case study data. Tools such as Microsoft Word, Microsoft Excel, Atlasti, and
NVivo are standard and robust software applications used to organize and process data
(Bree & Gallagher, 2016; Ose, 2016). According to Bree and Gallagher (2016), Microsoft
Excel is a standard tool used to organize, code, and classify data for the thematic analysis
used in analyzing qualitative data. Microsoft Excel is an electronic software application
used primarily for creating electronic documents and allows researchers to organize and
analyze semistructured data into workbooks (Ose, 2016). The Microsoft Excel
application is a standard tool researchers use to promote triangulation (Bree & Gallagher,
2016; Robins & Eisen, 2017; Saunders et al., 2016). I used the Microsoft Excel software
to capture, store, sort, code, and analyze participants’ responses and to review the
documentation data to reveal themes and trends.
Following the participant interviews, I organized data by first creating generic
Microsoft Excel workbook folders for each participant using alphanumeric pseudonym
labels such as Par1 through Par 5 to protect personal identification and to ensure
confidentiality. Compiling, categorizing, labeling, and storing data in a usable, accessible
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form is the first step of data organization (Castleberry & Nolen, 2018). I compiled the
study data by (a) pasting the raw participant audio-recorded interview responses in
Microsoft Excel, (b) use descriptive headings such as participant codes, question numbers
and corresponding responses, (c) compile interview notes and processes with a focus on
workflows and participant mannerisms that signify greater importance of the subject
matter,(d) compile document data such as surveillance reports that support the existing
medical device surveillance process and performance metrics, and (e) label the
transcriptions using participant color codes, question numbers, and responses. I
disassembled the data by reading the transcripts to identify categories and gave each
category a code name, including any unexpected exemplars. I reassembled the data into
groups in a second sequential Microsoft Excel workbook folder by repeating the coding
data for each participant interview and by identifying categories and patterns across all
participant interviews. I created a workbook document in Microsoft Excel and set up
sequential workbook folders to organize data for each participant. I organized and sorted
the data into categories and logically coded the text to allow for patterns to emerge for
accurate theme analysis.
For each participant workbook folder, I created consecutive Microsoft Excel
workbook folders to separate the raw data collection from data processing categories for
corresponding thematic data analysis. I embed hyperlinks to connect each supporting
workbook folder file to the result Microsoft Excel document to establish single storage
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location access. Each Microsoft Excel subfolder workbook was labeled with an
alphanumeric participant identification code to store raw participant transcript data,
relevant documents for each interview question, and iterative themes generated using
Microsoft Excel and color coding for each participant.
Data Analysis
The first step to analyzing data is establishing an analysis strategy. Data analysis
planning and defining the analysis tools are critical for case studies and include
triangulation and thematic analysis strategies (Hoeber & Shaw, 2017). I used
methodological triangulation and thematic analysis as a strategy to analyze the qualitative
data to produce significant themes in response to the research question. Researchers who
engage in the methodological triangulation of data from several sources help ensure data
reliability and validity (Abdalla, Oliveira, Azevedo, & Gonzalez, 2018). Collecting data
from more than one source is a way to achieve triangulation and validate the study’s
findings (Rosenthal, 2016). I ensured methodological triangulation by collecting and
analyzing relevant data from the semistructured interviews and the documents.
Thematic analysis is a data coding method to analyze large sets of textual data.
The purpose of thematic analysis is to identify meaningful or emerging themes or
patterns across the textual data set to answer the research question (Castleberry & Nolen,
2018; Saunders et al., 2016; Yin, 2018). In qualitative research, the researcher applies an
iterative data analysis process of preparing and sequentially coding data to determine
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patterns of meaning (Vaismoradi, Jones, Turunen, & Snelgrove, 2016). According to
Vaismoradi et al. (2016), thematic analysis is a systematic and continual process of
developing data codes to explore and interpret descriptive phenomenon meaning through
the emergence of significant themes. I followed the five data analysis steps recommended
by Yin (2018), which include (a) compiling, (b) disassembling, (c) reassembling, (d)
interpreting, and (e) generalize conclusions to analyze the data accurately. I used the
Microsoft Excel software application to complete the thematic data analysis. According
to Bree and Gallagher (2016), using Microsoft Excel for thematic analysis is a practical
approach to code and classify data for analyzing qualitative material. Using Microsoft
Excel to help conduct thematic analysis is simple and accessible without the complexity
of having to learn new software applications.
Conducting a thematic analysis is an iterative process. The thematic analysis
involves creating data categories for emerging themes and analyzing the data further to
determine subthemes (Vaismoradi et al., 2016). Kozleski (2017) posited that using the
software as a labeling and coding tool in identifying themes and subthemes is practical. I
analyzed the study data using Microsoft Excel to compile, sort, and reduce the data into
color-coded categories to identify emerging themes. For each interview data analysis, I
followed the steps below.
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1. Read the collected data for understanding.
2. Pasted the interview audio files verbatim into a Microsoft Excel workbook
folder.
3. Prepared the Microsoft Excel document workbook for coding.
4. Coded data into categories using colored labels.
5. Prepared the coded data for sorting into categories.
6. Sorted the coded data into logical categories.
7. Combined similarly coded categories.
8. Sorted the coded categories by frequency.
9. Interpreted the data to reveal patterns of meaning and identified emerging
themes.
10. Identified overarching themes.
11. Compared the data against other studies using the BPR conceptual framework
and with the other study’s findings.
12. Reported the findings and drew general conclusions.
I used Microsoft Excel to determine emerging themes using color-coding to
identify patterns and to compare emerging trends with existing research and through the
lens of the conceptual framework of BPR. I followed a sequential process and added
consecutive Microsoft Excel workbook folders for each thematic analysis iteration to
easily see the previous analyses for faster and more accurate identification. I referred to
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my literature review, conceptual framework, and the research question to help interpret
the data to draw conclusions. Researchers draw conclusions from the analysis of data
obtained through conducting the study and through exploring the existing data (Bree &
Gallagher, 2016; Yin, 2018). Performing a consistent and thorough thematic analysis of
the data is a process that researchers use to verify the validity of the emerging themes.
I delineated study data themes and derived meaning by interpreting the interview
data analysis codes regarding adverse medical device events surveillance regarding
Hammer’s BPR concept and existing works. Using the five phases of data analysis,
researchers have an opportunity to reflect on the research question and how the data
analysis connects to the conceptual framework and existing literature (Gallagher, 2016;
Vaismoradi et al., 2016; Yin, 2018). The final phase of the data analysis is when the
researcher develops a conclusion from the findings. The study findings may improve
business practices that support processes to reduce adverse medical events from medical
device implants.
Reliability and Validity
Reliability and validity are essential components of all qualitative studies. Two
critical research elements that apply to qualitative studies to ensure the data’s adequacy,
trustworthiness, and accuracy (Cypress, 2017; Spiers, Morse, Olson, Mayan, & Barrett,
2018). Researchers engage in the methodological triangulation of data from several
sources to ensure data reliability and validity (Abdalla, Oliveira, Azevedo, & Gonzalez,
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2018). The researcher is responsible for creating a quality study through the process of
providing accurate interpretations and eliminating personal bias to ensure a study’s
reliability and validity (Bengtsson, 2016; Cypress, 2017). My strategy to enhance
reliability and validity included: (a) an interview protocol, (b) member checking, (c)
methodological triangulation, and (d) achieving data saturation. Reliability comprised
primarily of dependability, and validity, which consists of credibility, transferability,
confirmability, and data saturation offer a deeper interpretation of rigor in qualitative
studies.
Reliability
Researchers use reliability methods in qualitative research to improve the
dependability and repeatability of the phenomenon under study. Reliability means
generating consistent results using the same study process design, methods, or practices
repeatedly and still achieving the same result (Cypress, 2017). An exhaustive description
of the research process is an indication of a dependable design that allows researchers to
produce reliable and consistent results (Cypress, 2017). Meticulously organizing and
coding data are steps researchers should use to demonstrate consistent data analysis,
which increases the dependability associated with repeatable outcomes (Amankwaa,
2016; Bengtsson, 2016). Methodological triangulation, using interview protocols, and
member checking are tools researchers can use to improve a study’s repeatability (Spiers
et al., 2018). I documented each step of the research process, used an interview protocol,
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asked probing questions, and engaged participants in member checking to ensure data
dependability and consistent findings. Member checking allows the researcher to verify
data accuracy with the participant after initial data collection takes place, and the material
has been summarized for participant analysis (Abdalla et al., 2018; Gaikwad, 2017). The
criteria used to select participants adds rigor and maximizes dependability (Amankwaa,
2016; Lavallee et al., 2017). Consistent data collection through several methods and
processes provided the same results when repeated and ensured reliability.
Validity
The design method used in a study also allows the researcher to demonstrate rigor
in a study. Gaining validity in a study relates to the links between data, results, and
findings (Terwel, Schuurman, & Loeve, 2018). The depth and understanding of the
phenomenon and the degree of the researcher’s ability to adhere to the chosen design is
necessary to produce in-context credibility and quality (Cypress, 2017). According to
Gaikwad (2017), rigor is a product of a study’s design aspects that include study method,
setting, participants, data collection techniques, existing literature, and data analysis
tools. Researchers must demonstrate rigor through affirming credibility, transferability,
confirmability, and data saturation.
Credibility
Qualitative researchers must demonstrate the credibility of a study. Researchers
can establish credibility during the data collection process to achieve greater confidence
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in the results (Amankwaa, 2016). According to Yin (2018), using an interview protocol,
methodological triangulation, and the member checking process improves the credibility
of the study’s results. Researchers use qualitative methods such as methodological
triangulation and member checking to confirm that the data used in a study is credible,
reliable, and truly represents solid results (Spiers et al., 2018). Member checking is a
method comprised of asking a participant clarifying questions to close any gaps in
interpretation (Fusch et al., 2017). I provided participants with a summary of my
interpretation of the transcript material to ensure my understanding of what they have
shared and to foster greater credibility in the study’s findings. To further ensure
credibility, I used an interview protocol for participant engagement consistency and
methodological triangulation by collecting data from several sources. I completed an
exhaustive literature review, collected interview data, and reviewed relevant documents
to establish the credibility of the findings.
Transferability
Transferability is an important component in conducting a qualitative study.
Transferability refers to the degree to which study results may apply to other researcher
study settings (Bengtsson, 2016; Marshall & Rossman, 2016). According to Bengtsson
(2016), the degree of potential study transferability relies on the level of result
dependability, credibility, and confirmability present. Researchers can increase
transferability in a study by meticulously documenting the research process and

100
collecting rich data to reach data saturation (Yin, 2018). Collecting rich data using the
appropriate participants and participant number ensures the accurate descriptions of the
phenomena under study, increasing transferability (Gaikwad, 2017). Varpio, Ajjawi,
Monrouxe, O’Brien, and Rees (2017) posited that methodological triangulation, member
checking, and reaching data saturation are ways for researchers to improve the transfer of
the results of a study to research settings. I meticulously documented the research process
step by step to augment confirmability to increase the potential for the transferability of
the findings to other settings.
Confirmability
Confirmability is a critical component that researchers strive to obtain to improve
the level of confidence in a study. According to Korstjens and Moser (2018), the level of
confidence to which other researchers can confirm the study’s findings establishes
confirmability. Researchers establish confirmability by avoiding bias and using
supporting evidence derived from an objective interpretation of the data (Korstjens &
Moser, 2018). The researcher can increase the confirmability of the study by using
methodological triangulation and member checking to evaluate the data accuracy to
ensure the trustworthiness of the results (Amankwaa, 2016). Brear (2019) posited that
member checking is a technique to establish qualitative research validity by checking the
accuracy of data in raw form through to the final results of the research. I used member
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checking, asked probing questions to achieve deep insight from the participants, and
attempted to be rigorously honest to achieve the confirmability of the study.
Data Saturation
Qualitative researchers aim to attain data saturation. Failure to reach data
saturation impacts the validity of a study (Fusch et al. 2018). Reaching data saturation is
the point in which no new themes appear, or no unique information emerges concerning
the phenomenon under study (Saunders et al., 2017). When a researcher reaches data
saturation, there is no need for more participants because there is enough data to explore
and understand the phenomenon under study (Fusch et al., 2018). A thorough description
of the processes used in the study by collecting relevant data until data saturation is
achieved promotes truthfulness, improves validity, and increases the degree of study
transferability (Bengtsson, 2016). Data saturation signifies that adequate data containing
all the information necessary to answer the research question and occurs when no new
themes or patterns emerge (Lowe, Norris, Farris, & Babbage, 2018). According to Fusch
et al. (2018), the application of methodological triangulation enables the researcher to
reach data saturation to enhance the quality of the study. I demonstrated methodological
triangulation by conducting semistructured interviews using a consistent interview
protocol, asking probing questions, reviewing relevant organization documentation, and
using member checking to reach data saturation. I continued to collect data from the
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participants until the data obtained became repetitious, and no new themes or patterns
became evident.
Transition and Summary
In Section 2, I outlined and documented the research design and execution of my
research study. The subsections of Section 2 consisted of an opening project statement,
the purpose statement, the role of the researcher, a review of the study participants, the
research methodology and design, population and sampling, ethical research, data
collection, data organization, data analysis, reliability, and validity. In Section 2, I
described and justified my study design and supported the objective of my study. I
selected a single qualitative case study design to explore the strategies hospital managers
use to redesign the implant recall notification process to reduce adverse medical events
and revision costs. My function was to serve as a professional primary data collection
instrument. I am responsible for using my experience and academic knowledge to
conduct ethical research while mitigating research bias. I implemented data collection
after I received IRB approval. After receiving IRB approval, I engaged with the selected
study design by first recruiting and interviewing participants following the guidelines of
the interview protocol. I collected interview data and reviewed organization documents
relevant to the study and used Microsoft Word Excel to organize data and complete
thematic coding for analysis. I used methodological triangulation, member checking, and
data saturation to enhance the reliability and validity study.
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In Section 3, I present my findings, discuss how the findings apply to professional
practice, the implications for social change, recommendations, reflections, and provide a
summary. In the presentation of results, I discuss the data analysis process, results, and
emerging themes that link to the literature and the BPR conceptual framework. Finally, I
conclude the section by explaining how the study results apply pragmatically and offer
recommendations for future study, reflective thoughts, and conclusions.

104
Section 3: Application to Professional Practice and Implications for Change
The purpose of this qualitative single case study was to explore strategies that
managers in hospital health care organizations used to redesign the implant recall
surveillance processes that reduced adverse medical events and revision costs. Hammer’s
(1990) business process reengineering (BPR) was used as the conceptual framework for
this study. To prompt study participants to provide rich information to address the
research question, I followed an interview protocol and used open-ended semistructured
interview questions. During the interview and member checking sessions, I asked probing
questions and reviewed documents relevant to the participant responses. The conduction
of interviews and gathering of data occurred until no new themes emerged, and enough
data was produced for theme analysis. Yin’s (2017) five stages of qualitative data
analysis to was used to define themes and draw conclusions from the data.
A qualitative analysis of data from interviews and documents resulted in four
themes: (a) effective data communication process, (b) central data repository integration,
(c) continuous process improvement, and (d) end-to-end surveillance process. The
findings were supported by data details collected from interviews and documents. This
section encompasses a presentation of the thematic data analysis of the results,
application for professional practice, and implications for social change. It also includes
reflections of my doctoral experience and closes with a final concluding statement.
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Presentation of the Findings
The principal research question for this study was: What strategies do hospital
managers use to redesign implant recall surveillance processes that reduced adverse
medical events and revision costs? The sample consisted of five hospital managers in the
northeastern United States, with strategic expertise in redesigning and executing medical
device surveillance processes. To obtain rich data from the five study participants I used
an interview protocol and conducted semistructured interviews containing open-ended
questions. Researchers use open-ended questions and ask probing questions in a
semistructured format to encourage participants to offer their experiences and
perspectives (Gaikwad, 2017; Rosenthal, 2016). Relevant organization documents related
to existing standard surveillance operating procedures and policies that managers use as a
process map to trigger actions that hospital managers should take during a medical device
recall notification were reviewed. To protect participants each received a code name,
Par1, Par2, Par3, Par4, and Par5 and the health care organization received the code name
H1. The conduction of interviews and collection of data occurred until data saturation
was reached, and no new themes emerged.
I analyzed all participant interview comments and detected emerging themes as
well as which themes were supported by relevant process workflow documents. I used a
5-step thematic analysis process to identify emerging common themes. I became familiar
with the data by reviewing the collected data, color coded unique keywords, identified
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code patterns, and combined codes to identify emerging themes. According to Bree and
Gallagher (2016), color coding qualitative data in an Excel workbook is an effective
method for identifying themes. Analysis of the collected data revealed that the adoption
of the strategic themes enhanced universal medical device surveillance processes that are
essential to monitoring device longitudinal data for patient safety. All themes support a
BPR model to improve device surveillance processes continuously. The four themes that
emerged from the data collection process included: (a) effective data communication
processes, (b) central data repository integration, (c) continuous process improvement,
and (d) end-to-end surveillance processes (see Tables 3 through 6 below).
Theme 1: Effective Data Communication Process
The first theme to emerge was implementing an effective data communication
process. The characteristics of an effective data communication process includes
delivering data to the exact destination with accuracy, in a timely manner, and without
real-time variation. All participants emphasized the importance of defining regulatory
and internal data communication processes as part of their strategy. All participants
expressed the concern regarding the use of an effective data communication process
strategy to establish persistent medical device data-sharing internally with other
departments and externally with manufacturers, vendors, distributors, FDA, insurance
plans, and the patient. Table 3 illustrates the most frequent strategies used by participants
regarding their effective data communication surveillance strategy.
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Table 3.
Participants’ Strategies for Effective Data Communication Process
Most frequent strategies
Continuous data-sharing

Participants
Par1, Par2, Par3, Par4, Par5

Frequency of occurrence
89

Continuous real-time data

Par1, Par3, Par4, Par5

65

Internal & external data

Par1, Par2, Par4, Par5

51

Theme 1 aligned with previous research that medical device surveillance and
delivery requires available evidence and standard communication protocols that increase
data sharing for communication effectiveness (see Sturmberg, 2018). Drozda et al. (2016)
also posited that the complex and stochastic aspects of health care data require
knowledge translation and communication that is unambiguous and effective for sharing
data. While further research by Alaba et al. (2017), illustrated that effective
communication is about establishing a continuous integrative network process that
incorporates interoperable data sharing communication software protocols between all
surveillance members for greater data visibility. Additionally, Sayle (2016) concurred
that data sharing requires the right communication network design and connecting
medical data rich resources is the best place to start medical device identification.
Establishing an internal and external communication process is an effective way to
increase data sharing capability in a rapidly change business environment (Salvoto &
Vassolo, 2017). Implementing an effective data communication process allows hospital
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organizations to obtain medical device performance feedback quickly, which helps
managers create strategies and objectives to achieve optimum results.
The preferred method among participants for effective data sharing was through a
real-time communication process using web services, electronic mail, and software
applications for alert and audit purposes. All participants articulated the importance of
combining internal and external resources to increase the effectiveness of data
communication for medical device surveillance. Par1 and Par5 indicated that exchanging
information continuously within both the organization and external businesses using
electronic communication web service tools provides real-time communication that is
essential for monitoring medical device performance and notifying a patient proactively
before an adverse event occurs. Additionally, Par2 stated, “Data-sharing must reach
beyond the internal organization walls to be effective and by using web based electronic
communication services, we are able to monitor medical devices with greater
transparency.” Par3’s response further confirmed the importance of effective
communication practices, “External data sharing is just as important as internal data
sharing for monitoring medical device performance and electronic communication using
web services is a great tool to share data.” The five participants consistently stated that
they used some form of electronic data communication, whether internally or externally,
as an effective strategy to mitigate adverse medical device risk and to control revision
costs. Par3 described the redesigned surveillance process strategy as an effective data
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communication process regarding internal and external relationships with manufacturers,
vendors, internal business resources, and end-users symbiotically for real-time
monitoring.
Managers combined innovative sustainable communication processes by linking
persistent data-sharing resources using software data-sharing applications to share data
continuously. According to Verstegen, Dailey-Hebert, Fonteijn, Clarebout, and Spruijt
(2018), combining data sources is an effective way for individuals to communicate in an
intensive continuously contributing manner for more in-depth discussions and to
brainstorm without guidance. Continuous real-time data communication is becoming a
practical reality for health care (Aceto, Persico, & Pescape, 2018). Participants
emphasized the importance of timely, constant real-time data communication and
assembling critical data information from device surveillance sources anywhere, anytime,
using connectivity anytime. Both Par1 and Par2 referenced the effectiveness of
implementing data communication processes across vertical and horizontal organization
barriers in a continuous real-time manner. Par3’s response further indicated the
importance of continuous real-time sharing and stated, “We need to establish a datasharing system that is continuous in real-time with complete transparency, visibility, and
accessibility to close the data communication effectiveness gap.” Par4 identified
streamlining the data integration process as important for smoothing the transmission of
data communication.
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Furthermore, participants indicated the importance of communication regarding
potential issues with devices. Par4 stated, “We follow explicit regulations and software
surveillance requirements for sharing postmarket recall notifications and revision
feedback data.” Similarly, Par5 responded that they used transparent data communication
pathways, such as the internet and private configured networks, to access proprietary
application data silos internally and externally as a strategy to mitigate risk and control of
medical device recalls and revisions. Par5 said, “We closed the disjointed data
communication gaps using Managed Recalls software to improve the medical device
surveillance data-sharing process and evolved from a passive, reactive surveillance
process to a more dynamic real-time surveillance process. Managers preferred a proactive
data-sharing communication process for informed decision-making.”
Additionally, proactive data communication may help managers mitigate the
impact of potential uncertainty. Par 4 stated, “Medical device data communication started
as a slow manual process that morphed into a timely internal and external process using
the Managed Recalls surveillance software application allowing managers to share and
access data to make informed decisions.” Par3 concurred by stating, “The surveillance
process continues to be disjointed and linearly constricted and the speed of data-sharing
communication must be addressed further to improve medical device surveillance
processes effective in the most comprehensive proactive way.” While Par1 stated, “We
have a variety of medical device data communication processes in place but it is basically
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an alert surveillance process and is not efficient from a real-time surveillance perspective
to trigger proactive activity to mitigate potential adverse medical events.” To address this
issue Par2 suggested increasing data communication effectiveness by merging real-time
data with medical diagnosis intervention to proactively reduce adverse medical device
events.
A review of documents supporting the participant interview responses illustrated
how the participants’ organization shared internal and external data regarding effective
data communication alignment between manufacturers, regulators, implementor
operations, and end-users to maximize process flow. The documents supported theme 1
as the information included within them provides managers with data-sharing
communication links between internal and external resources. For example, medical
device surveillance documents illustrated FDA medical device recall data, message
logging, and managers response to department physicians who were accountable for
implanting the device. Information found in the surveillance documents also indicated
historical recalls of similar devices and current device inventory information.
Viewing theme 1 via the BPR conceptual framework further supported the
findings. In health systems, researchers commonly use BPR to identify and redesign
ongoing process models to enhance service quality by improving process speed and
safety, while reducing costs (Grocott et al., 2017). The effective data communication
process strategy H1 managers used aligned with BPR because the radical surveillance
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process changed the process and caused the implementation of a software management
system.
Better data communication is essential for managers to make critical decisions to
mitigate adverse medical device events. Managers who redesign strategies and
persistently integrate combinations of ubiquitous business ecosystems employ radical
change but can create better process performance and holistic value for the end-user
(Dedehayir, Ortt, & Seppanen, 2017). The resolution of medical device lifecycle
surveillance could be beneficial to health care managers who lack strategies for
combining relevant data sources and communicating the information effectively to meet
care demands to reduce adverse medical events and revision costs.
Developing an efficient and less complex data-sharing process is critical for a
successful and efficient data-sharing communication surveillance process. Medical
device surveillance managers leverage process improvement and reengineering methods
to reduce and manage complexity (Szmelter, 2017). The findings aligned with the
literature review indicating the surveillance evolution of evidence-based medical
processes that produce data managers could use as an informing mechanism to make
effective medical, resource, cost, and reimbursement decisions regarding medical
devices. The result of such implementation is potentially better device quality, treatment
diagnosis, and reimbursement enquiring through an effective data communication
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process. As the business world becomes increasing interconnected, managers can
leverage the capability of data communication.
Theme 2: Central Data Repository Integration
The second theme that emerged from the analysis of interview and document data
was the need for a central data repository. A central data repository is a collection of
diverse stored data from existing database sources integrated into a single location for
sharing information throughout an organization. According to all participants, a central
data repository integration was critical because integrating various internal and external
data sources for single source decentralized accessibility potentially closes the gap
between static and actionable medical device surveillance information for recall decision
making. Table 4 illustrates the most frequent responses from participants regarding their
central data repository integration surveillance strategy.
Table 4.
Participants’ Strategies for Central Data Repository Integration
Most frequent strategies
Data access centralization

Participants
Par1, Par2, Par3, Par4, Par5

Frequency of occurrence
73

Health record & UDI data
interfacing
Integration of data &
distribution

Par1, Par3, Par4, Par5

58

Par1, Par2, Par3, Par4

44

This theme supported previous research including Dagher et al. (2018), who
argued that accessing electronic health care data in real-time requires the right
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connectivity via technology using the right integration platform to collect decentralized
data into a central accessible repository. Desveaux and Gagliardi (2018), also posited that
medical device surveillance data collection and notification functionality requires
integrating various data repositories to reduce information accessibility fragmentation
and discrepancies. Further research by Trajkovic and Milosevic (2018) indicated that the
interconnected business environments demand sharing data through less complex
standardized central processes to capture and exploit knowledge through a single
resource. The primary need is to integrate data from ubiquitous sources and process the
data into an insightful central repository platform as a single accessible source to improve
performance, speed, and service.
All five participants have used and implemented interface application tools as a
strategy to integrate data repositories to centralize data access for improving the medical
device life cycle surveillance process. Additionally, all participants articulated the need to
integrate proprietary software data repository silos to further enhance the device
surveillance process outside of the FDA database. Par1 stated, “The implementation of
technology solutions to integrate data repositories from manufacturers, electronic health
record data silos, insurance claims, providers, surgery protocols, device UDI, and patient
wearable mobile devices is necessary to establish a robust life cycle surveillance
process.” Par2 supported Par1’s assertion and stated, “Using integration technology to
capture the device UDI and combining that data with health system historical record data
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establishes a way to make device recall decisions based on evidence.” Table 4 illustrates
the participants most frequently used data repository integration strategies. All
participants posited that integrating data sources into a centralized repository improves
continuity within the medical device surveillance process and promotes a sustainable
model moving forward. Par1 stated, “The UDI regulation establishes fundamental and
interfaceable medical device identification parameters to conduct surveillance to identify
and find the patient and product on a global scale.” Figure 3 illustrates the current
documented and compiled medical device surveillance integration strategy at H1.

Figure 3. Current medical device surveillance integration strategy compiled from process
mapping documents and interview findings.
Figure 3 is a depiction of the current medical surveillance process managers use
based on process mapping documents and information gathered during the interviews.
The illustration outlines the data workflow that H1 managers use to monitor medical
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device surveillance activity. The Managed Recalls application links the external medical
device data from the FDA and device manufacturer into a central data repository. The
central data repository serves as a surveillance integration tool for managers to monitor
device performance failures. The software application automatically gathers device UDI
inventory data and notifies the surveillance manager via electronic messaging. The
manager reviews the inventory and sends an electronic message to all clinical and device
supporting departments to remove device from use and to contact the patient for revision.
All five participants stated they used the process flow found in Figure 3 for
medical device surveillance as a strategy to monitor device recalls but emphasized the
need to redesign the data repository integration to improve the surveillance process. All
participants concurred that the redesigned medical device surveillance process should
incorporate a centralized device data repository to increase the speed of recall notification
to reduce adverse medical events and the potential increases in costs related to revisions
or liabilities. Par5 stated, “The medical device surveillance strategy was designed to share
data information in a standard way by integrating data into a centralized repository for
decentralized access,” However, Par2 indicated the lack of a centralized device repository
and stated, “We need to establish a device repository that is trusted like a world trust data
bank that is centralized, updated persistently, and is accessible for fast location of device
and patient to reduce medical device adverse events proactively.”
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All participants emphasized the use of a secure distributed ledger technology
(DLT), which is a database shared and synchronized across multiple sites, to establish an
interoperable, digitally persistent, centralized data repository fit for single access purpose
but decentralized for multiple users. For example, Par4 stated, “We are investigating the
use of DLT as a secure protocol for medical device data storage and transactions.” A
review of process mapping documents and compiled interview data regarding data
repository integration architecture confirmed the effort to connect disparate data sources
to one central accessible data location is beneficial. Figure 4 illustrates the medical device
surveillance integration strategy managers are investigating as the desired state based on
process mapping documents and compiled interview data yet plans to move in this
direction have not been established completely.
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Figure 4. Desired future state of medical device central data repository integration
strategy based on process documentation and compiled interview data.
Figure 4 is a depiction of further investigation of medical device central data
repository integration based on process mapping documents and information gathered
during the interviews. The illustration in Figure 4 outlines the data workflow strategy that
H1 managers are developing to establish a completely integrated medical device central
data repository. The main difference compared to the existing surveillance process
illustrated in Figure 3 is the central data repository having bidirectional decentralized data
communication access. Other workflow components to note include integration with the
patient electronic health record, billing, claims processing and health plan payor to
complete the device surveillance life-cycle. Par2 stated, “Designing a quality medical
device postmarket surveillance process is about data integration and simultaneously
sharing data from a central repository back to all caregiver stakeholders.” Par3 added,
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…using DLT integration establishes a digitally persistent data repository transfer
protocol that is a secure, valid, and trustworthy. Data transparency, visibility, and
availability is critical to improving the speed at which the information is
disseminated effectively to all recipients in the caregiver communication chain.
While Par5 posited, “Establishing valid process guidelines for integrating various
databases are critical to producing consistent data-sharing results to maintain process
quality.” According to Vijayasree et al. (2017), a process validation protocol ensures
consistent results and the effectiveness of the process design for producing the desired
quality results. The use of process validation establishes a way to control and document
evidence that the performance of the process design is effective or indicates a need for
change.
A review of process mapping documents supported the desired future state
medical surveillance process in Figure 4 as did data collected from the participant
interviews. Sources of supporting desired state process documents included illustrations
from power point slide deck presentations to inform executive management of the
process improvements and raw whiteboard drawings. The medical device surveillance
software documentation illustrated that all external alert and device recall data source
repository interfaces allow managers to continuously monitor medical device recall data
and revision alerts. Par2 stated, “Each capturing data system enhances the transparency
and visibility of medical device surveillance process by allowing managers to identify the
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device, user, and collect reports of device performance events from several integrated
data systems into a central database.” A review of the internal process mappings of the
current medical device surveillance process before and after the redesign confirmed the
participant interview data.
These findings are supported by the literature. Sharing medical device life cycle
data is desirable and involves redesigning and building an accessible, integrated data
repository platform to collect and distribute information without communication
restrictions (Sayle, 2016). Medical device surveillance managers can use the BPR
framework as a model to redesign and centralize device data repositories. Researchers,
such as Brown et al. (2015), Rensnic et al. (2017) and Lau (2017), posited that linking
data sources creates value by gaining informative decision insights to reduce medical
device errors, improve adverse medical events reporting, provide rapid resolution of
recalls, and reduce revision costs. Managers can leverage process reengineering methods
to reduce complexity and manage data from multiple data repositories.
Each study participant discussed the importance of tracking medical device UDI
information from a central data repository. According to Ibrahim and Dimick (2017), the
most significant process redesign included UDI data interoperability and transparency
between the manufacturer, the point of care, electronic health records, and claims to
confirm that medical device data is centrally available. Basatneh et al. (2018) posited that
a centralized device data platform simplifies device communication variation and the
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adoption of standard protocols to enable device connection that eliminates the burden of
integration configuration and accessibility away from the care givers and consumers of
care. Additionally, Dagher et al. (2018) posited that redesigning a connectivity platform
using central access or DLT is a radical strategy to address health care data accessibility,
integrity, and security to centralize data collection. Data collected using the blockchain or
DLT is important for processing and sharing by addressing speed, scale, and convenience
concerns. Managers can use a central data repository integration strategy to develop
further an intelligent ubiquitous communicative surveillance platform to simultaneously
coordinate multiple devices, manufacturers, service providers, patients, and numerous
protocols for processing data into insightful, proactive surveillance levers to reduce
adverse medical events and revision costs.
Theme 3: Continuous Process Improvement
Continuous process improvement emerged as a theme for avoiding the occurrence
of medical device recall surveillance errors. Continuous process improvement is about
improving the quality and reducing process complexity through implementing
incremental breakthrough changes over time. According to participants, a continuous
process improvement strategy was critical because the goal of a medical device
surveillance process is to stay updated with the current business technology and operation
environment. Table 5 illustrates the most frequent responses from participants regarding
their continuous process improvement surveillance strategy.
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Table 5.
Participants’ Strategies for Continuous Process Improvement
Most frequent strategies
Regulatory UDI labeling

Participants
Par1, Par2, Par3, Par4, Par5

Frequency of occurrence
74

Process continuity

Par1, Par2, Par4, Par5

47

Eliminate fragmentation

Par1, Par2, Par3, Par4

45

The need for assurance in quality medical devices has brought focus to the need
for the postmarket surveillance process to stay up to date regarding device design and
regulations while reducing recall response time and reducing revision costs (Mendonca,
Gallagher, & Hendryx, 2019). Continuous diagnosis validation magnifies the need for an
effective clinical surveillance process for the health industry (Vijayasree et al. 2017).
Diagnostic device manufacturers are not just suppliers of medical devices but must
facilitate the quality management of the device through continuous process improvement
with the health care service (Holdsworth, Glisson, & Choo, 2019). Mendonca et al.
(2019) posited that quality, performance, and costs of device contribute to the value of
medical devices. The need for assurance in medical device quality, regulation
compliance, cost reduction, and performance has increased focus on postmarket device
surveillance. Table 5 illustrates the most frequent responses from participants regarding
their continuous process improvement strategy for medical device surveillance.
All participants posited that consistently monitoring UDI medical device data is
the foundation and common denominator of their continuous process improvement
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strategy to remain competent with changing device surveillance technologies.
Participants asserted medical device surveillance managers should use a continuous
investigative, iterative process implementation strategy approach to improve device
monitoring. Par1 stated,
…if the difference between the redesigned UDI surveillance process and legacy
systems was greater from a safety improvement perspective, then the new system
was adopted and integrated into the overall system as a process improvement;
otherwise the legacy system remained in place.
While Par2 said, “Existing surveillance mechanisms do not usually shed light on the
denominator of the device used but rather the numerator of issues reported.” According to
Javaid and Haleem (2019), the medical device industry exploits the manufacturing of
newly customized implants and requires continuous surveillance process improvements
to remove data fragmentation and increase system communication continuity for all
devices using a complete sustainable monitoring system. Current business technology
produces a need for continuous process improvement which is critical for reducing data
communication complexity to fill device surveillance gaps.
Medical device technology and patient needs change. Continuous augmentation of
the medical device surveillance process fulfils the individual requirements of the patient,
medical industry, and regulatory reporting with optimized time and cost (Javaid &
Haleem, 2019). Par3 stated, “Our strategy is not to become complacent and accept an
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underperforming medical device surveillance process which can induce managers to
potentially become insensitive to errors which normalizes process deviance.” Further
supporting the strategy identified by Par3, Par5 stated,
…the existing medical device surveillance process is a matrix of integrated parts
that includes manual intervention and automating some of these parts in
conjunction with diagnosis intervention is the continuous process improvement
strategy balance we try to achieve each day.
Developing a continuous process improvement strategy for medical device surveillance
must involve all stakeholders, including all individuals who authorized, implanted, and
had contact with the device from the manufacturer to the patient, to create a higher degree
of ownership and accountability. Equally important is continuously improving the
process to integrate human intervention, automation, and data repositories to help
managers understand the data and make decisions regarding the medical device life-cycle
based on informed insights.
A review of documents and medical device packaging illustrated medical devices
using different labeling formats and barcodes. Documentation review of UDI inventory
logs that illustrated medical device label codes supported the participant interview data
and confirmed the need to continuously improve the UDI format process to develop one
source of data truth. Par2 stated, “Standard UDI medical device labeling provides
managers with a valid device identification number to match the physical product to the
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patient, and right now there is a lot of trust in the process and can always be improved,”
while a review of documents indicated that UDI identification is not standard. However,
a continuous process improvement strategy could ensure medical device validation that
the device implanted in the patient is the device under recall.
The study findings correlated with results in the literature review and confirmed
that a continuous process improvement strategy is an innovative approach to generate
new medical device surveillance processes through the integration of technologies,
intelligent software applications, and monitoring software as developments in the medical
field advance. Continuous process improvement is an integral part of BPR and fits with
Hammer’s (1990) redesigning business process concept. The application of the BPR
model enables the facilitation of exploring the unpredictable nature of medical device
surveillance processes and the need for continuous improvement. According to Hammer
(1990), managers can use the BPR model to redesign and create process value through
improved performance, speed, and service. In the literature review, Alaba et al. (2017)
supported a continuous innovative technology approach to establish an integrative
medical device surveillance network that incorporates continuous interoperable
communication software and manual caregiver intervention protocols between all
surveillance members. This approach serves to collect both physical and internet
connected device data that may influence device performance (Alaba et al., 2017).
Additionally, Tyndall and Tyndall (2018) showed that innovative medical device
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surveillance strategies that adopt a combination of continuous improvement monitoring
services helped managers track and exchange information flow, make inquiries, and share
database information without compromising database silo functionality. The whole
concept is to continually improve the medical device surveillance process
comprehensively.
Theme 4: End-to-End Surveillance
The final theme that emerged from an analysis of interview and document data
was end-to-end surveillance of medical devices. End-to-end surveillance of medical
devices is a process used to reliably monitor the life-cycle of the device. Managers use
data collection software called Managed Recalls as an end-to-end surveillance strategy to
continuously and automatically collect medical device surveillance data from internal and
external resources. Table 6 illustrates the most frequent responses from participants
regarding their end-to-end surveillance strategy.
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Table 6
Participants’ Strategies for End-to-End Surveillance
Most frequent strategies
Device real-time life-cycle
monitoring
Software & IoT

Participants
Par1, Par3, Par4, Par5

Frequency of occurrence
74

Par1, Par2, Par3, Par4

47

Internet web services,
Blockchain & DLT

Par1, Par2, Par4, Par5

45

All participants stated that software functionality is limited to subscription
members and lacks interface ability with abundant information data resources, such as
electronic health records, claims, provider notes, and patient feedback, for complete
medical device surveillance visibility. Par5 articulated,
…the health industry is behind the commercial retail industry regarding product
surveillance. For example, Amazon can track a tomato from farm to table. Still,
we have difficulty monitoring the life-cycle of a medical device in a patient’s
body from the moment of implantation.
Par3 indicated that technology is available, but proprietary software creates data silos,
and present health care data-sharing standards are not allowing healthcare managers to
implement integrated end-to-end surveillance processes to gather pertinent device lifecycle information to make informed decisions.
Hospital managers realize that data resource silos alone are not enough to provide
a comprehensive medical device surveillance process that creates value from a
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postmarket perspective. The use of UDI establishes a consistent identification system
foundation for medical devices that ensures that the available information about an
implant is accessible throughout the health care supply chain (Brown, Kaushiva, & Chi,
2015; Resnic et al., 2017). Par2 said, “as of now, the UDI is the only source of truth that
establishes a feedback mechanism that links the medical evidence to the device.” Par4
posited,
…our strategy is to continuously evaluate and use an end-to-end surveillance
process that includes central repository access for effective UDI data sharing and
the plethora of internal and external medical device data resources including
wearable monitoring devices such as the Apple iWatch.
The revolution of medical device advancements provides physicians with new therapeutic
opportunities prompting hospital managers to embrace new medical device surveillance
process strategies (Javaid & Haleem, 2019).
All participants mentioned the need to augment the end-to-end medical device
surveillance strategy through implementing the Internet of things (IoT) and internet cloud
web services. Par1 stated,
…we need to redesign the medical device surveillance process strategy and
simplify connectivity to disparate data resources and data exchange with the help
of new software, sensors, robots, and other advanced information technologies
such as blockchain and DLT for real-time surveillance.
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Par2 shared comparable insights, “We can create new opportunities and innovative new
routes for patient care by redesigning the existing surveillance process to include
software, internet web services, blockchain, and DLT technology to establish an inclusive
end-to-end surveillance process.”
Other key findings from the participants included the identification of challenges
to implementing a redesigned end-to-end medical device surveillance process. These
challenges include resistance from vendors to share patient health care data stored in
proprietary data silos and lack of management buy-in to implement new technologies
such as FHIR, blockchain, and distributed ledger technology as leading issues. Par3
stated, “we need to extract data from rich sources and exploit the data to generate useful
information, and this requires an end-to-end medical device surveillance process.”
Interoperable resources such as FHIR, blockchain, and DLT allow managers to query and
share database information beyond data ecosystem silos without compromising database
functionality (Tyndall & Tyndall, 2018). Additionally, all participants shared that their
organization is currently utilizing software tools designed for the medical device industry
surveillance as it relates to design controls and risk management of medical devices for
reactive rather than proactive measures. All participants said that the strategy is to patch
legacy software tools together to form a complex, fragmented, end-to-end network
configured for limited access. Par2 stated, “our current medical device surveillance
process is a patchwork of various manual and software solutions to fill in real-time
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surveillance gaps and to remove data silos is our strategy to improve data transparency
and access for end-to-end surveillance.” Fragmentation of the surveillance
interoperability process usually leads to inefficient use of data, people, process, and
technology as multiple resources work independently without instantaneous information
knowledge from other postmarket databases.
I reviewed documents that outlined an end-to-end digital interoperable data
strategy and supported data collected from the participants during the interviews. The
study findings aligned with results in the literature review and confirmed that the end-toend surveillance process strategy is an approach that provides managers with the agility
to integrate various technologies to create an intelligent surveillance ecosystem. The use
of Hammer’s (1990) BPR concept allows managers to identify and evaluate the medical
device surveillance processes across all organization data communication links to
distinguish value and non-value activities. Research completed by Dagher et al. (2018)
indicated that the evolution of internet connectivity and applications such as blockchain
and DLT technology have allowed managers to redesign the medical device surveillance
process from a passive data collection system to a real-time data system. Furthermore,
Dagher et al. (2018) posited that real-time medical device data accessibility provides
managers with end-to-end device life-cycle surveillance to collect valuable patient
medical device data and process the data into insightful patterns and passing information
to participants, caregivers, and device users. Additionally, Sayle (2016) illustrated that
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safety is the desirable medical device surveillance process value proposition and involves
redesigning and building a platform to collect device data for speed, scale, and
convenience, and sharing medical device life cycle data on a wide scale. Following
Hammer’s BPR concept, medical device surveillance managers in this study could then
eliminate non-value activities and implement activities that add value.
Overall, critical strategies managers implemented to improve medical device
surveillance included standard medical device UDI labeling, capturing the medical device
UDI label data, adding the UDI data to the patient medical record and claim, developing
central data repository access, using IT software called Managed Recalls to improve the
management and surveillance of medical devices to ensure meeting the safety demands of
the patient, and end-to-end surveillance using current business social technology to
capture real-time mobile device data. Regarding real-time medical device monitoring,
research by Al-Gayar and Shubber (2019) indicated that medical social medial platforms
deliver high medical monitoring by combining social networking systems, e-learning,
mobile health, and health software applications for interaction empowerment resulting in
safer product performance. The outcomes from this study could have a positive impact on
how medical device manufacturers design devices, monitor the device lifecycle, and issue
recalls, thereby reducing adverse medical events and revision costs.
These study findings tie to my conceptual framework and support manager use of
BPR to redesign the communication and integration technology to gather ubiquitous
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medical device surveillance information throughout the product life to reduce device
revision costs. According to Javid and Haleem (2019), the benefit of collecting and using
medical device data in more efficient ways provide process design flexibility to maximize
multiple health care functions to reduce costs. Some notable functions to improve
medical device surveillance operational efficiencies include minimizing nonvalue added
workflow protocols. Three critical components that reduce medical device cost are
communication technologies, process integration, and sustainable outcomes (Gawankar,
Gunasekaran, & Kamble, 2020). Human and technology interactions, such as a device
scanning process, monitoring real-time device performance, and paperwork reduction
through digitalization can reduce operational cost by decreasing medical emergency
management time, which reduces surgery time and risk (Javid & Haleem, 2019, Kamble
et al.,2019). The added value of integrating fragmented medical device surveillance
processes and sharing data to make insightful decisions proactively, potentially reduces
device revision costs.
The current study findings confirm and extend the knowledge in the discipline of
medical device surveillance and other health care services that can benefit from data
traceability. A potential extended health care service is tracking diseases and viruses.
Monitoring contagious viruses such as Wuhan Novel Coronavirus is possible through
using distributed data access technology (Dai, Zheng, & Zhang, 2020). The findings
indicate that managers have an opportunity to use the BPR concept to redesign the
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surveillance process by applying advanced information and communication technologies
to enhance medical device surveillance strategies that support social and economic
sustainability. According to Alladi, Chamola, Parizi, and Choo (2019), the adoption of
advanced information and communication technologies allows managers to monitor and
verify processes by orchestrating resources, distributing insightful data, and augmenting
existing processes to add human flexibility and capability. Dai et al. (2020) posited that
as the technology to collect, analyze, distribute, and communicate information changes,
the taxonomy of the medical device surveillance process potentially evolves into the next
generation of monitoring transparency linking treatment directly to the patient. To fully
utilize and apply the findings herein, further research is recommended to address the
anticipated process challenges of implementing resilient technology techniques that have
been mentioned as transformative for medical device surveillance.
Applications to Professional Practice
The objective of the study was to explore strategies successful managers use to
reduce adverse medical events and costs from implanted medical devices. The results of
this study are significant to professional practice because the strategic objectives that
emerged from this study in the current business environment may help hospital business
managers enhance patient care, safety, and reduce adverse medical events and revision
costs across the clinical industry. The findings of the study may add value to the success
of manager strategies by considering the following four themes: (a) effective data
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communication process, (b) central data repository integration, (c) continuous process
improvement, and (d) end-to-end surveillance process.
The study results may help managers gain a better understanding and insights
regarding good medical device surveillance practices, which may help them detect device
failures proactively before a catastrophic adverse medical event and improve patient
safety. Each theme supports medical device surveillance managers to increase their
insightful knowledge from sufficient monitoring processes to mitigate potential device
risks. Hospital managers can potentially reduce device risk by implementing an effective
data communication process that allows data-sharing from internal and external sources
in real-time for greater device performance visibility. Secondly, developing a ubiquitous
central data repository without proprietary application constraints engages all caregiver
stakeholders, and continuous process improvement ensures that managers update
surveillance technologies that are compatible with the current business environment.
Finally, an end-to-end surveillance process encompasses the complete life-cycle of
medical devices and creates patient safety satisfaction.
Hospital medical device surveillance managers may find some of the themes to be
strategies they could use to potentially deliver better health care. For example, the
business application of using a central data repository for UDI information from the
manufacturer to the patient that is accessible for all caregivers is the sensible and
conscientious thing to do for patients. The UDI adds transparency and trackability to the
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specific devices that are used in the patient’s care and make it more likely that problems
with implant devices can be detected, located, and responded to promptly. UDI data in all
device-related data repositories can enable better device identification methods, better
reporting on the denominators or total products used in a population, and better
longitudinal outcomes for patients treated by multiple providers and institutions. Another
business application strategy is the integration of other health electronic data repository
systems, including the manufacturer, FDA, EHR, mobile cloud data, third party payers,
and claims. Hospital organizations can use a combination of databases and technology,
such as blockchain and DLT, to conduct safety surveillance activities that will allow
managers to make scientifically sound or evidence-based assessments of device safety in
the future. Combining all the medical device data sources and transmitting the
information through a bidirectional connected communication network engages all
caregiver stakeholders and can provide a continuous device life-cycle surveillance
process. The four themes presented provided the best practices for improving medical
device surveillance consistency to match patient performance demands in the current
business environment of the health industry. The themes that emerged fill the knowledge
gaps about redesigning medical device surveillance strategies to reduce adverse medical
events and revision costs.
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Implications for Social Change
Exploring strategies hospital managers use to redesign implant recall surveillance
processes to reduce adverse event revision costs has implications for positive social
change. The study results could help hospital managers improve medical device
surveillance performance to produce several benefits, including regulatory compliance,
better patient implant outcomes that stimulate business, and employment, thereby
contributing to economic stability and improved social conditions. By developing and
implementing a consistent medical device surveillance process, hospital managers can
satisfy the patient demand for enhancing the quality of life through safer products. The
use of quality products could reduce the number of recalls that may harm individuals who
use the product, the organization’s reputation, and profitability success (Wei, Wang, Yu,
& Zhao, 2019). Organizations that deliver safer implant products build a sustainable
business where individuals and the local population can benefit from a healthier
community, create business stability, and employment growth.
Additionally, improved medical device surveillance process strategies to meet
business and consumer needs across the United States and globally may allow managers
to contribute to product development and quality professionals from across the world.
Managers that share medical device surveillance strategies, tactics, and technologies
potentially accelerate product research to ensure compliance, and promote product
quality to reduce user vulnerability and costs. Successful businesses may contribute to the
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advancement of social and human conditions by providing sustainable employment
opportunities for individuals in local communities and stimulating economic growth
(Polonsky, Grau, & McDonald, 2016). Satisfied patients may remain in local
communities that provide sustainable employment and financial stability. Successful
businesses and employed individuals within a community provide the government with
tax revenue that can use to develop programs to enhance social and economic inclusion,
which improves the social condition for underserved individuals, organizations, and
communities.
Recommendations for Action
The business problem addressed in this study was that ineffective medical device
surveillance processes increase adverse medical events and revision costs. The
continuous challenge for managers is to implement a standard medical device
surveillance strategy that integrates multiple business processes to overcome the
problems of data repository silos and time consistency for delivering persistent insights,
validity, and auditability without communication dissemination restrictions. To achieve
an effective surveillance strategic process for medical devices, I recommend that
managers map the work processes to identify the pitfalls and bottlenecks in the
surveillance process value stream. Secondly, I recommend a strategy that targets
measures and activities to address the pitfalls and bottlenecks using best practices to
improve data communication processes and centralizing data repository access using
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technology, such as blockchain and DLT to decentralize access control. Thirdly, I
recommend managers use a targeted iterative implementation strategy and continuous
evaluation of performance measures to improve the process to match the level of
potential device vulnerability.
The findings and recommendations that I propose in this study are relevant to
medical device surveillance managers in the health industry, manufacturers, health plans,
organizational leaders, caregivers, researchers, and scholars. To disseminate the study
findings, I will provide participants and the organization leaders with an executive
summary of the study results. I will discuss the results of the research with health care
stakeholders, hospital managers, and professional consultants. I intend to submit articles
for publication in the Journal of Medical Devices and the Journal of the American
Medical Association.
Recommendations for Further Research
The limitations of this study included a single case study and a sample size of five
hospital managers who implemented strategies to mitigate adverse medical device events
and revision costs in the health care industry. Future researchers could expand the scope
of this study by using a multiple case study design and a larger sample size of hospital
managers. Another limitation was the transferability of the findings to other health care
organizations because of the limited study scope. I recommend that future researchers
should consider using a sample of hospital managers in a different health care system
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who use various surveillance strategies to monitor adverse medical events and revision
costs. Future researchers could use a quantitative method to examine the significance of
the relationships between an assortment of device surveillance performance variables,
such as the number of medical device implant recall notifications, type of medical
implant, number of adverse medical events, number of medical implant revisions, cost of
corrections, readmission rates, and death. For this study, I only explored the strategies
used by hospital managers. Perhaps future researchers could further expand this study by
exploring other industry surveillance processes in use today. I recommend further
research with an organization like Amazon to monitor item distribution lifecycles from
manufacturer to customer to mitigate damage risk and warranty replacement and try to
understand how these findings might apply universally.
Reflections
I have worked in professional technical business roles for over 36 years, and the
doctoral program has been one of my most challenging but rewarding life experiences.
There were times when I thought about pausing indefinitely because of the amount of
stress and time sacrificed away from family and friends. I learned immensely from the
doctoral process, especially how to become a better researcher and writer. The doctoral
process helped me grow professionally and personally. I developed a scholarly reflective
approach to appreciate, understand, and value other individual perspectives about
business and life social issues.
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The literature review and my lack of knowledge about the study topic minimized
personal biases and supported my claims, as stated in the introduction. This study
provided me with an opportunity to learn outside of my experience comfort zone.
Additionally, I used an interview protocol and the same open-ended interview questions
for each participant to diminish personal preference. I was surprised how excited and
willing the study participants were to offer their perspectives regarding the subject
matter.
The themes that emerged from the interview process were very insightful and
connected back to the BPR conceptual framework. Insights that emerged and resonated
with me were the dependency hospital managers place on timely data communication
processes, not assuming more data without filters creates useful information and using
current business technology in the health industry. I am satisfied with the results of this
study because I believe the study will contribute to better health care. Future researchers
could expand this study by researching other hospital organizations that monitor adverse
medical events from implanted medical devices to reduce revision costs.
Working in the medical industry over the past decade of my career, I became
motivated to complete this study by the prevalent medical implant surveillance issues
facing patients and the desire to change health care even in a small way. The research
conducted for this study was intense, and I experienced time setbacks regarding lengthier
than expected study review processes and a lack of clarity regarding the order of the
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study process. However, my chair mentor served as a good role model and provided me
with guidance, motivation, and emotional support to get me through the most frustrating
experiences. I am also thankful for the relationships I fostered with colleagues that will
continue beyond this study process. I have met some incredible individuals along the path
and look forward to the positive impact we will have on our communities from changes
stemming from our studies.
Conclusion
Through the lens of BPR, the purpose of this single case qualitative study was to explore
strategies hospital managers use to redesign implant recall surveillance processes that
reduced adverse medical events and revision costs. I used purposeful sampling to identify
study participants and collected data using semistructured interviews with five medical
device surveillance managers from one hospital organization. I used member checking to
enhance the study reliability, and each participant provided supporting documents that I
used for triangulation. Four themes emerged from the study data analysis: (a) effective
data communication process, (b) central data repository integration, (c) continuous
process improvement, and (d) end-to-end surveillance process. Each theme supports
hospital managers seeking to develop strategies to improve medical device surveillance
business process practices, which potentially reduce adverse medical events, revision
costs, and creates positive social change by improving individual life quality through
long term disease health management.
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Existing medical device surveillance process strategies are not standard, or consistent,
and prone to insufficient data communication, data access, continuous process
improvement, and comprehensive end-to-end device surveillance. Medical device
surveillance managers can use the study results to augment their existing device
monitoring management capabilities if there is a lack of adequate surveillance process
insights to improve device performance and reduce the safety risk. The medical device
surveillance process is complex, and informative data can add enormous value. Capturing
the right data continuously in real-time, using current business technology, extracting
useful information, and communicating the results requires a continuous comprehensive
end-to-end process improvement strategy to stay current with the ever-changing business
environment and end-user needs. Because managers have redesigned the existing medical
device surveillance processes for collecting data from multiple sources, employing an
iterative and empirical approach serves as a strategy to understanding how the current
surveillance process is performing and what changes potentially improve the process.
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Appendix A: Interview Protocol
The purpose of the interview is for interviewees to answer the research questions
regarding strategies hospital managers use to redesign implant recall notifications to
reduce adverse medical events and revision costs. I will execute the following steps for
each participant interview after IRB approval an obtaining permission from the
organization executive leadership to gain access to participants.
1. I will identify and solicit individual participants willing to participate in the
study by emailing each potential participant a recruitment letter and an
informed consent form with details of the study. The email will contain
instructions for the potential participant to respond via email if willing to take
part in the study.
2. If the participant understands the study well enough to make a conscious
decision to participate in the study, the participant can respond by replying to
the email with the words I Consent. By responding with the words, I Consent,
the participant acknowledges understanding the nature of the study, the
potential risks as a participant, and the means by which participant identity
will be kept confidential. The consent also indicates that the participant is 18
years old or older and gives permission and consent to voluntarily serve as a
participant in the study described.
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3. If the potential participant has not responded within five days, I will contact
each participant via email or telephone call to explain the study, review the
consent form, and answer questions. I will explain the informed consent
participation components of the study in detail including the length of time
needed for the interview and the purpose of audio recording of the interview. I
will explain that handwritten notes will be taken if the participant prefers not
to be audio recorded.
4. Following further informed consent explanation, the participant can reply to
the informed consent email with the words I Consent.
5. Once consent is received, I will schedule interviews.
6. I will email the interview questions before the scheduled interview.
7. I will explain to each participant in an email that the study interview is
voluntary and that a verbal or electronic withdraw notice from any participant
is acceptable at any time without ramifications even after data collection.
8. I will provide my contact information for each participant in an email to
contact me if the participant decides to withdraw.
9. I will reiterate the purpose of the study before conducting interviews.
10. I will start scheduling interviews within 48 hours of the participants consent.
11. I will conduct the interview in private offices during convenient times. I will
use pseudonym participant coding to protect the participant anonymity. For
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example, I will use Par1, Par2, Par3, and Par4 for all four interview
participants to protect participant data confidentiality and privacy. I will
explain that I will be the only one to know the true participant identities and
responsible for keeping identities confidential.
12. At the start of each participant interview, I will begin with a brief review of
the informed consent. I will give an overview of the research, the purpose, and
time requirements.
13. I will request participant permission to review relevant documents that
support their responses relating to strategies to redesign medical device
surveillance such as charts, graphs, spread sheets, or other internal documents
that the participant determines as important or adds to the participants point of
view.
14. I will audio record the interview and start asking open-ended interview
questions and probing questions to obtain rich information responses from the
participant. If a participant chooses not to be recorded, I will take scrupulous
handwritten notes.
15. At the conclusion of the interview, I will remind the participant that within 48
hours, I will schedule a 30-minute member checking session for more detailed
response interpretation. Before the member checking meeting, I will provide a
written summary of my interpretation of the interview responses for review to
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validate responses and to make corrections as needed to reflect the participate
perspective. During the member checking meeting, I will answer any
additional participant questions or concerns and give the participant the
opportunity to interpret any other responses.
16. I will end the interview by asking each participant if anything else can be
added to the data collection and thank the participant for taking time to
participate.
Interview Questions
1. How would you describe the existing surveillance process for medical device
recalls?
2. What are your hospital’s strategies to redesign the medical device surveillance
process to reduce adverse medical events and revision costs?
3. What strategies were the most and least effective?
4. What situations influenced a change in strategy leading to redesigning the
medical device surveillance process?
5. What were the barriers you encountered while implementing the strategies to
redesign the medical device surveillance process?
6. What strategies did you use to overcome the critical process redesign
challenges to mitigate medical device recall surveillance errors?
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7. How does your organization redesign medical device surveillance processes for
tracking consistency in a failsafe manner?
8. How did you measure the effectiveness of the redesigned medical device
surveillance process to reduce adverse medical events?
9. What else can you share with me about your organization’s strategies to
redesign medical device recall surveillance processes to reduce adverse
medical events and possible revision costs?
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Appendix C: Informed Consent for Participants over 18 Years of Age
Invitation to Participate and Background Description of the Study
As a doctoral student at Walden University, I am concluding a research study to explore
strategies hospital managers use to redesign the medical device surveillance process to
reduce adverse medical events and revision costs using a single case study of a non-profit
hospital system located in Northeast Pennsylvania. I am also an information technology
manager in a non-supervisory role within the hospital system where I plan to complete
my research. My present employment role is to investigate an advanced image viewing
solution for the enterprise and to increase information technology application
productivity. My role is separate from the study research involving the medical device
surveillance process for the reduction of adverse medical events
I am inviting you to be a part of this study involving a select sample of managers of a
hospital system successfully using post market medical device surveillance process
strategies to reduce adverse medical events and revision costs. I obtained your name and
contact information from the organization executive leadership. The purpose of the
informed consent form is to outline the invitation, study background, purpose,
procedures, voluntary nature, study benefits, non-compensation participation statement,
confidentiality, contact information, and obtaining consent. I am seeking to interview
hospital managers who fit the following expertise criteria:
• Must have 2 years management experience and familiar with medical
device post market surveillance.
• Must support decision making to redesign the business processes.
• Must have successfully supported the implementation of medical device
surveillance process redesign strategies.
Meeting the above inclusion criteria is the requirement for study participation.
Description of Procedure
Your participation will involve an audio-recorded interview of approximately 45 minutes
in duration, preferably at your place of business. I will ask participants to share nonconfidential information and documentation regarding medical device post market
surveillance process workflow activities including device manufacturer and FDA recall
notification letters, spreadsheets or other systems that managers use to monitor recall
notification letters, internal recall notification time logs, internal notification emails,
device removal or correction completion logs, aging medical device recall logs, unique
device identification (UDI) data acquired in recalls, and the business process workflow
mapping that illustrates the end-to-end device recall surveillance notification process.
The review of relevant operational documents will be used to compare and support the
interview data and to minimize bias. You will have an opportunity to perform member
checking, by validating a summary and adding additional response interpretation of the
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interview data to be e-mailed to you by the researcher. Member checking is a follow-up
interview of approximately 30 minutes in duration to ensure accurate representation of
your responses. After completion of the study, you will be provided with an executive
summary of no more than two pages. The provided summary is a brief description of
study findings, recommendations, and conclusions. All data collected will be coded and
documents redacted to protect your identity, data confidentiality, and privacy. Study data,
electronic and paper, will be maintained in a locked, confidential file by the researcher
for a period of 5 years after final dissertation approval. After that time, the documents
and data will be destroyed appropriately.
Voluntary Nature of the Study, Risks and Inconvenience
There is no reasonably foreseeable risk to you beyond those encountered in daily life
such as fatigue, stress, or becoming upset. Participating in this study poses minimal risk
to your safety or well-being. However, if you do feel fatigued, stressed, or uncomfortable,
you can do any of the following: you can take a break and continue later, decline to
answer any questions, you can choose to stop the interview, or you can remove yourself
from the study without implication.
Benefits
Although there may be no direct benefit to you, the potential benefit of your participation
is to help advance the understanding of present medical device post market surveillance
process strategies to reduce adverse medical events and revision costs within a hospital
enterprise system.
Financial Payments (or other) Considerations
No financial (or other) consideration is being offered to the hospital or managers for
participation in the study.
Confidentiality and Privacy
Any and all information obtained from you during the study will be confidential and will
not be used for any other purpose than research. The organization and each participant
will be assigned a unique code to protect the participant data confidentiality and privacy.
I will use H1 for the organization and Par1 through Par4 for each participant. Your
privacy will always be protected. Any personally identifiable information (i.e. hospital
and manager’s names) will only be available to the primary researcher. I will have the
ethical responsibility to keep identities confidential. All data obtained from the
participant during and after the study will be confidential. The organization and
participant privacy will always be protected. The data collected may be used in aggregate
as part of publications and papers related to the medical device post market surveillance
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process strategies some hospital systems use to promote reduction in adverse medical
events and revision costs. No individuals will be identified in any reports of the findings.
Voluntary Participation
While I am enthusiastic about the study and your involvement as a manager of medical
device recall surveillance, participation in this study is voluntary. If you choose not to
participate or withdraw from the study at any time, there are no penalties or loss of
benefit to yourself.
Contacts and Questions
If you have any questions concerning the research study, please email me at
gary.zack@waldenu.edu or call my cellular telephone at 570-7026-6846. If you want to
discuss privately about your rights as a participant, you can call the Research Participant
Advocate at Walden University at 612-312-1210 or email IRB@mail.waldenu.edu.
Walden University’s IRB approval number for this study is 02-28-20-0614432 and
expires on the given IRB date of February 27, 2021.
Obtaining Your Consent
If you understand the study well enough to make a conscious decision to participate in
the study, please indicate your consent by replying to this email and accompanying
attachments with the words I consent. By responding with the words, I consent, the
participant acknowledges understanding the nature of the study, the potential risks as a
participant, and the means by which participant identity and data will be kept confidential
and private. The consent also indicates that the participant is 18 years old or older and
gives permission and consent to voluntarily serve as a participant in the study described.
Please do not hesitate to contact me with any questions or concerns.
Sincerely,
Gary J. Zack, MS
Walden University Doctoral Student
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Appendix D: Participant Recruitment Letter
Participant Recruitment Letter
Dear [Hospital Manager],
My name is Gary Zack, and I am a doctoral student pursuing a Doctor of Business
Administration (DBA) at Walden University. To fulfill the requirements of the DBA
program, I am conducting a doctoral research study that results in new knowledge,
insight, or practice to address a business problem. My research topic is to explore
strategies hospital systems managers use to redesign implant recall surveillance processes
to reduce adverse medical events and revision costs using a single case study of a nonprofit hospital system located in Northeast Pennsylvania. The contribution of this study is
to provide hospital managers with a better understanding of how successful post market
device surveillance management strategies could contribute to reducing adverse medical
events from implanted medical devices.
I am seeking to interview hospital managers who fit the following criteria:
• Must have 2 years management experience and be familiar with medical
device post market surveillance.
• Must support decision making to redesign the business processes.
• Must have successfully supported the implementation of medical device
surveillance process redesign strategies.
The expectation for participation involves a 45 minute face-to-face interview, asking the
participants to share any relevant documents that support their interview responses, and a
30 minute member checking follow up session. The interview will include nine openended questions (attached with this email) that you can provide your unique perceptive
understanding on this research topic. Once the study is approved and posted in ProQuest
database scholarly journal, I will share results and findings with the participant, other
management executives, and other scholars. Participation in this study is voluntary and
confidential. The participant can remove themselves from the study at any time during
the research process without repercussions.
If you meet to above criteria and are interested in participating in this valuable research,
please reply to the email accompanying this attachment. Upon receiving your reply of
interest, I will contact you via email to provide additional information related to the
research process and schedule the interview at a time and location of your convenience.
Please read the enclosed consent form carefully and ask any questions that you may have
before accepting the invitation. I appreciate taking the time to consider this invitation and
please contact me directly with any concerns at 570-706-6846 or ary.zack@waldenu.edu.
Sincerely,
Gary J. Zack, MS,
Doctoral Candidate, Walden University
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Appendix E: Site Approval Letter
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